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The study presented in this thesis originated from a clinical observation. During our 
clinical work in an inpatient treatment facility for refugees and asylum seekers in the 
Netherlands we encountered many patients suffering from symptoms of posttraumatic 
stress disorder (PTSD) in conjunction with symptoms of chronic psychosis, especially 
delusions and hallucinations. These traumatized patients, with a poor response to 
antipsychotic medication, had developed PTSD and subsequently, sooner or later, 
psychotic symptoms as well.  These patients were referred to our clinic by colleagues 
who time and again wondered what the correct diagnosis was and what the best 
treatment policy should be. One of those referring psychiatrists wrote:
Our impression is that the symptoms are strongly related to PTSD. 
However the paranoid delusions and acoustic and visual hallucinations could 
also fit the DSM-IV diagnosis of ‘schizophrenia’. 
On the other hand many facts plea against this diagnosis:
-  the non-bizarre content of the patients perceptions
-  the normal way of making contact
-  the age of the client (onset of first psychosis at 35 years of age)
-  the course of the disorder
-   the fact that the traumatic events and the disruption of this patients life may 
constitute a reasonable explanation of the experienced symptoms. 
The questions that were raised about the diagnosis of these patients among referring 
psychiatrists, as well as, the repeatedly encountered treatment resistance of the 
chronic psychotic symptoms, paved the way for the main questions of this thesis. The 
ultimate goal would be: to find adequate and effective treatment options. However 
before such an endeavor could be undertaken another important question emerged: 
what is the most appropriate diagnostic position of this manifestation of posttraumatic 
stress disorder and subsequent psychosis? Is it a form of (late onset) schizophrenia, 
a complex PTSD,  a special kind of affective psychotic disorder, or is it a diagnostic 
entity on its own? 
 Thus the goal of this thesis is to either refute or find evidence for the validity of this 
complex clinical picture as a separate diagnostic entity. Or more specific: is PTSD 
with secondary psychotic features a diagnostic entity on its own or could this 
combination of symptoms be appropriately described by familiar and already existing 
diagnostic categories? 
 First, we had to define a clear focus of our research. Therefore, we studied the 
present state of knowledge in the realm of trauma and psychosis. This was done by 




4.  In earlier studies a discussion emerged regarding highly prevalent comorbid 
psychiatric conditions in patients suffering from PTSD, like major depressive 
disorder. Maybe, these secondary psychotic symptoms were part of a psychotic 
depression. Most studies found no evidence for this hypothesis, but some did. 
This issue needed attention since it was as yet unresolved. Therefore in Chapter 
5 we explored the associations between psychotic features in PTSD-SP and 
other comorbid psychiatric conditions. In addition, we investigated two related 
issues that could account for the presence of psychotic features in PTSD-SP: 1. 
severity of the PTSD re-experiencing cluster, and 2. type and severity of the 
traumatic events.
5.  In a previous study, Hamner and Gold (14) reported an increased level of blood 
plasma activity of dopamine β-hydroxylase (DβH) in patients with PTSD and 
psychotic symptoms compared to healthy controls and PTSD patients without 
psychosis, suggesting that the psychotic features in patients suffering from 
PTSD are not attributed to major depressive disorder with psychotic features 
since in those patients blood plasma activity of DβH has shown to be decreased. 
In  Chapter 6, we replicated and expanded this study by using 1. a larger sample 
size of PTSD-SP patients, 2. adding a group of patients suffering from 
schizophrenia and 3. controlling for possible group differences in the DβH 
-1021C/T gene polymorfism since this polymorphism accounts for up to 52% of 
the inter-individual variations in plasma DβH activity.
In order to answers these questions (Table 1) we designed the following study.
Study design
We designed a cross sectional study in which we recruited patients from two mental 
health hospitals in the Netherlands1 that provide inpatient treatment for asylum 
seekers and refugees from different parts of the world. In the screening phase, 
recently admitted patients meeting the following criteria were asked to participate: 
being a refugee/asylum seeker, 16 years or older, and at least one DSM-IV PTSD 
symptom or at least one psychotic symptom. After oral and written description of the 
study to the participants, written informed consent was obtained, in some cases 
together with the patient’s representative. All study procedures were approved by the 
Mental Health Institutions Ethical Review Board (METIGG).
1   The Phoenix Centre, Pro Persona, Wolfheze and de Vonk, Centrum 45, Noordwijkerhout. These are the 
only two national inpatient treatment facilities for refugees and asylumseekers.
presence of an increasing scientific interest in the complex interrelationships between 
trauma and psychosis. Available studies could be divided in three interrelated groups 
of subtopics. Most studies deal with patients suffering from schizophrenia and 
subsequently became traumatized and developed PTSD (1-4).  A second group of 
studies focused on childhood trauma leading to psychosis and schizophrenia in 
adulthood (5-8).  A third group of studies focused on adult patients who first developed 
posttraumatic stress disorder and after that started to suffer from secondary 
co-morbid psychotic features, especially chronic hallucinations and delusions. Given 
the goal of our own study we were mainly interested in this last group.
 An increasing number of papers had been published on this group. However, 
none of these studies systematically assessed and tested the validity of the emerging 
concept of ‘posttraumatic stress disorder with secondary psychotic features’ (9-12). 
 In Chapter 2 we aimed at finding all available empirical studies and analyzed 
them according to the six criteria of Robins and Guze (13) in order to establish the 
diagnostic validity of PTSD-SP as a separate diagnostic entity. In Chapter 3 we 
expanded this search with a focus on neurobiological aspects. These two chapters 
not only summarized what was known about PTSD-SP but also showed us the main 
gaps in our knowledge and the issues that needed additional empirical research.
Research questions
In our study we focused on five issues that needed further inquiry:
1.  Previous studies were almost exclusively limited to male outpatient war veterans 
from the U.S. exposed to combat-related trauma. We therefore focused on a 
different and more diverse population: a multi-ethnic sample of refugees, both 
male and female, who had been exposed to a wide range of traumas, not 
exclusively combat-related. 
2.  Previous epidemiological studies focusing on psychosis and PTSD were often 
based on the lifetime presence of PTSD, psychosis and other comorbid 
conditions, and did not take into account the temporal relationships between 
these conditions. Thus, we explicitly aimed at recording the temporal relationship 
between PTSD and psychotic symptoms focusing our study on those patients 
with a PTSD diagnosis that was followed by the onset of psychosis. 
3.  Previous studies revealed that patients suffering from PTSD-SP had psychotic 
features similar but not necessarily identical to schizophrenia. Therefore, we 
wanted to compare the psychotic features in both groups in order to determine 




We recruited three groups of patients (PTSD-SP, PTSD, schizophrenia) and one 
group of healthy controls:
1. The group of patients with posttraumatic stress disorder and secondary 
psychotic features, the ‘PTSD-SP-group’, was defined as patients with a DSM-IV 
diagnosis of PTSD and psychotic symptoms, in whom the onset of PTSD 
preceded the onset of psychosis. Patients with sub-threshold or no PTSD were 
excluded from this group as well as patients who suffered from PTSD without 
psychotic symptoms. We carefully distinguished psychotic symptoms from 
(dissociative) flashback episodes with illusions and hallucinations while reliving 
the experience. These latter symptoms were interpreted as part of the 
conventional DSM-IV diagnostic criteria for PTSD. 
2. The group of PTSD patients without current or life time psychotic features 
constituted the ‘PTSD group’. Patients of this group met the PTSD criteria of the 
DSM IV and had no positive psychotic features outside re-experiencing episodes. 
3. The ‘schizophrenia group’ was defined as those patients meeting DSM-IV 
criteria of schizophrenia but without a DSM-IV diagnosis of PTSD prior to the 
onset of the first psychotic episode. Patients in this group were allowed to meet 
criteria for DSM-IV PTSD only if this disorder had an onset clearly after the onset 
of the schizophrenia diagnosis.
4. Healthy controls were recruited from non-genetically related family members, 
friends or acquaintances as well as subjects from regional refugee asylums. 
They were screened for the presence of psychiatric disorders with the Composite 
International Diagnostic Interview (CIDI), developed by the WHO(17, 18). The CIDI 
is a cross-culturally valid diagnostic screening instrument and is well-fitted for the 
general population. Subjects meeting CIDI diagnostic criteria for any psychiatric 
diagnosis were excluded.
In all groups, patients with bipolar disorder, organic mental disorders or malingering 
were excluded.
Symptom Measures
In both patient groups with psychotic symptoms (PTSD-SP and schizophrenia), 
psychotic symptoms were assessed with the Positive and Negative Syndrome Scale 
(PANSS)(19). In addition, the psychotic symptom rating scale (PSYRATS) was 
administered to assess delusions and hallucinations in more detail (20). Since the 
PSYRATS covers only delusions and acoustic hallucinations, we added analogous 
items to assess visual hallucinations as well. 
 The Clinician Administered PTSD Scale (CAPS) was used for a detailed 
assessment of the frequency and intensity of PTSD symptoms in the PTSD and the 
Diagnostic assessment and group allocation
After screening and informed consent, symptoms, main diagnoses and comorbid 
disorders were assessed with the Schedules for Clinical Assessment in Neuropsy-
chiatry (SCAN)(15). The SCAN was preferred over the Structured Clinical Interview for 
DSM (SCID) because in the SCAN no diagnosis-driven a priori grouping of symptoms 
is enforced. Moreover, the SCAN has been shown to be cross-culturally valid and 
applicable(16). In addition, the Clinical History Schedule (CHS) of the SCAN provides 
detailed information on the onset of symptoms and disorders.
Table 1  Overview
Chapter Title Research Question
2 Validity of ‘posttraumatic 
stress disorder with secondary 
psychotic features’: a review of 
the evidence
What is the current evidence supporting 
the validity of ‘posttraumatic stress 
disorder with psychotic features’?
3 ‘Posttraumatic stress disorder 
with secondary psychotic 
features’: neurobiological 
findings
What is the current neurobiological 
evidence supporting the validity of 
‘posttraumatic stress disorder with 
psychotic features’?
4 Clinical differences between 
psychosis in ‘posttraumatic 
stress disorder with secondary 
psychotic features’ and 
schizophrenia among 
refugees
Can chronic psychosis in PTSD-SP 
be distinguished from psychosis in 
schizophrenia by clinical features and 
trauma history? 
5 Psychosis in PTSD Can the presence of psychotic features 
in PTSD-SP be explained by psychiatric 
comorbidity, by more severe PTSD re-
experiencing-symptoms, or by more 
severe or a specific type of traumatic 
events?
6 Plasma dopamine-beta-
hydroxylase activity is not 
increased in posttraumatic 
stress disorder with secondary 
psychotic features
Is genotype controlled (DBH-1021 C>T) 
plasma dopamine-beta-hydroxylase 
activity increased in posttraumatic stress 
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PTSD-SP group (21). The CAPS was performed by an experienced psychiatrist 
blinded for diagnostic group status. The CAPS also contains a trauma-list in order to 
assess more general traumatic events, not specific for refugees.
 The experienced traumatic events were measured in all groups with the trauma 
scale of the Harvard Trauma Questionnaire (HTQ) which contains a traumatic events 
scale specifically designed for trauma’s experienced by adult refugees (22). The HTQ 
has proven cross-cultural reliability and validity for the groups under study (23). 
The Hopkins Symptoms Checklist (HSCL-25) was used to assess the presence and 
severity of anxiety and depressive symptoms in all four groups (24). The HSCL-25 has 
proven cross-cultural reliability and validity for the groups under study (23). 
 All symptom measures were administered by interviewers that were blind for 
diagnostic group status. Professional interpreters assisted in 80% of all interviews. 
Dopamine β hydroxylase activity and DBH genotyping 
Blood samples were taken from all participants. All blood samples were collected 
between 9 and 11 a.m. to avoid potential diurnal variation of DβH plasma activity in 
individuals. Blood samples were prepared and stored awaiting batch wise analysis. 
All laboratory staff was blinded for group status. 
 Assessment of DβH activity was carried out at the Radboud University Nijmegen 
Medical Center, Department of Laboratory Medicine. Enzyme activity was expressed 
in units per liter; 1 U/L was defined as the amount of enzyme needed to convert 1M 
dopamine into 1M noradrenalin per minute.
 Genotyping of the DβH  1021 C>T (rs1611115) polymorphism  was carried out at 
the Department of Human Genetics of the Radboud University Nijmegen Medical 
Centre, in a laboratory, which has a quality certification according to CCKL criteria. 
The genotyping assay had been validated before use. 
Outline of the thesis
The results of our literature reviews are reported in Chapters 2 and 3, whereas the 
findings of the current study are reported in Chapters 4, 5 and 6. In the general 
discussion (Chapter 7) we reassess the question whether PTSD-SP is a valid 
diagnostic entity by combining the existing literature and our own findings together 
with findings from new studies published in the last five years. 
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Validity of ‘posttraumatic stress  
disorder with secondary psychotic 
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Introduction
There is an increasing interest in the complex interrelationships between trauma and 
psychosis. Studies on this topic vary from traumatic psychotic experiences leading to 
posttraumatic stress disorder to childhood trauma leading to psychosis and 
schizophrenia in adulthood (1-4). This study focuses on adult patients suffering from 
posttraumatic stress disorder with secondary co-morbid psychotic features, 
especially chronic hallucinations and delusions. These patients have no history of 
schizophrenia prior to the traumatic event and psychotic symptoms emerged after 
the onset of PTSD. Although an increasing number of papers have been published 
on the presence of secondary psychotic features in patients suffering from 
posttraumatic stress disorder, none of these studies systematically assessed and 
tested the validity of the emerging concept of “posttraumatic stress disorder with 
secondary psychotic features” (5-13). The present study originated from the need of 
many psychiatrists who experience diagnostic uncertainty and lack of therapeutic 
success with this complex clinical condition that, according to them, does not 
correspond with schizophrenia (14, 15). An adequate diagnostic interpretation is 
needed before reasonable treatment-choices can be made or new and specific 
treatment methods can be developed and tested. The lack of some salient features 
of schizophrenia, the normal pre-trauma functioning, and the lack of success of 
routine treatments leads to the question whether the diagnostic concept “posttraumatic 
stress disorder with (secondary) psychotic features” (PTSD-SP) represents a valid 
separate diagnostic entity.
 In this context, validity refers to the degree to which a diagnostic concept 
represents a discrete disease entity. Psychiatry generally lacks a gold standard that 
can be used to directly establish the validity of a psychiatric disorder. It, therefore, has 
to rely on indirect validation strategies. These strategies were delineated for the first 
time in the seminal paper of Robins and Guze (5) and further refined by others (6-9). 
The following criteria for a valid diagnostic entity can be distinguished:
1. Clinical description: identification and description of a syndrome;
2. Delineation: clear boundaries with other, related, syndromes;
3. Course: typical course and outcome of a syndrome;
4. Treatment response: typical treatment effect of a syndrome;
5. Family studies: particular syndrome runs in families;
6. Biological correlates/laboratory studies: distinctive biological characteristics 
related to a syndrome.
Abstract
Objective: To review the evidence from empirical studies regarding the validity of 
“posttraumatic stress disorder with secondary psychotic features” (PTSD-SP) as a 
separate diagnostic entity. 
Method: The authors performed a review tracing publications published between 
1980 and January 2008. 
Results: Twenty-four comparative studies were included. From these studies, 
PTSD-SP is emerging as a syndrome that consists of posttraumatic stress disorder 
followed in time by the additional appearance of psychotic features. The psychotic 
features are not confined to episodes of re-experiencing, but remain present 
continuously. PTSD-SP seems to have some biological features differentiating it from 
schizophrenia and PTSD, e.g. there are differences in smooth pursuit eye movement 
patterns, concentrations of corticotrophin-releasing factor and dopamine beta- 
hydroxylase activity. 
Conclusion: There is currently not yet full support for PTSD-SP as a nosological 
entity. However, the delineation of PTSD-SP from other psychiatric syndromes is 
notable and biological studies seem to support the validity as a separate diagnostic 
entity.
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Results
The results are presented according to the six validity criteria of Robins and Guze (16, 20). 
(See table 2 for the number of studies addressing validity criteria).
Clinical description
To what extent has the clinical condition of PTSD-SP been described?
 Symptoms. In several comparative population studies patients present a 
full-blown PTSD after traumatic events first, and subsequently report hallucinations 
and delusions (11, 13, 14, 20). The nature of these hallucinations is generally 
(71-100%) related to traumatic events, e.g. voices of dead buddies calling for help. 
The content of delusions is mainly paranoid/persecutory (16, 17, 29). These 
psychotic features are pervasive and chronic and do not occur exclusively in the 
context of a re-experiencing episode (14, 16). Several studies mention the presence 
of bizarre behavior. Formal thought disorders (e.g. flight of ideas, loose associations) 
are almost never reported. 
 Severity.  Patients with PTSD-SP suffer from a higher burden of disease than 
patients with PTSD without psychotic features and the illness severity of PTSD-SP is 
similar to schizophrenia (14, 16, 17, 19). However, the presence or absence of 
psychotic features is not associated with the severity of PTSD as measured by the 
Clinician Administered PTSD Scale (CAPS) (14). The intensity of paranoid thinking 
and agitation is much higher in PTSD-SP patients than in patients with PTSD without 
psychosis or patients with psychotic disorder without PTSD (18). 
 Trauma. The nature and severity of the traumatic events are not associated with 
the presence or absence of psychotic features following PTSD (25, 27). In only one 
study, a positive correlation was found between the severity of the traumatic events 
and the presence of psychotic features (11). In this study, however, ethnicity could be 
a confounder: Hispanic American veterans with PTSD were more likely to develop 
positive psychotic features, but they also had more severe traumatic exposures.
 Ethnicity. Hispanic Americans as well as African Americans displayed an 
increased incidence of PTSD-SP compared to Caucasians, even after controlling for 
differences in the nature and severity of the traumatic experiences, sociodemographic 
characteristics and family history of psychiatric illness (9, 22, 23). 
 Personality disorders. In one study personality disorders were investigated as a 
possible risk factor for PTSD-SP. In a group of Croatian war veterans and soldiers still 
in military service suffering from PTSD, psychotic symptoms were more often found 
among patients without co-morbid personality disorders (29). 
 Age of onset. The age of onset of PTSD-SP has not been studied systematically. 
From all studies included in this review PTSD-SP emerges in early adulthood or later 
in life (e.g. in war veterans). However, reports of childhood trauma, PTSD and 
Aims of the study
This study aimed to evaluate the empirical studies regarding the validity of PTSD-SP 
as a separate diagnostic entity against these six criteria.
Material and methods
Publications in English, French, German, Dutch, and Spanish, issued between 1980 
and January 2008 were traced, using the databases MEDLINE, PsycINFO, EMBASE 
Psychiatry, and Published International Literature On Traumatic Stress (PILOTS). The 
following full-text terms were used: ‘PTSD’, ‘posttraumatic stress disorder’, ‘stress 
disorders, posttraumatic’, ‘psychological trauma’, each combined with ‘psychosis’, 
‘psychotic’, ‘schizophrenia’, ‘hallucination’, ‘hallucinations’, ‘delusion’, ‘delusions’, and 
‘reality testing’. Publications were screened, using the title and the abstract for 
relevance to the topic, i.e. PTSD and psychotic features. The reference lists of the 
publications were used to find additional studies.
 A total of 184 publications on posttraumatic stress disorder, trauma and 
psychosis, or psychotic features were identified. From these 184 papers, 126 were 
excluded because of a primary focus on (a) psychosis following traumatic brain injury 
without PTSD (n=11), (b) schizophrenia or other psychotic disorders preceding the 
onset of PTSD (PTSD following (first onset) psychosis, traumatic reactions to 
psychotic illness, post-psychotic PTSD) (n=74), (c) (childhood) trauma leading to 
psychosis without a diagnosis of PTSD (n=30), and (d) psychosis and trauma in 
childhood or adolescence (age < 18 years; n=11). This selection process resulted in 
58 publications on adult patients suffering from primary PTSD with secondary 
psychotic features (PTSD-SP). Of these 58 publications 16 were excluded because 
they did not contain original empirical data. In addition we excluded all studies (n=18) 
below level three of the Oxford Centre for Evidence-based Medicine levels of evidence 
(10). This means that we included systematic reviews, randomized controlled trials, 
(prospective, retrospective as well as non-consecutive) cohort studies, and ecological 
studies. We excluded case-series and papers based on expert opinions
 Following this selection process, 24 studies remained (Table 1). This review is 
based on these 24 comparative studies with empirical data and minimum requirements 
regarding the level of evidence. Fourteen studies were performed in U.S. male war 
veterans, suffering from combat-related PTSD, and for the most part treated in 
outpatient facilities. Seven studies included females or civilians. 
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Table 1   Characteristics of all published empirical studies on PTSD-SP  
(in chronological order) meeting evidence-level three or higher  
(no less than case-control studies)
Year Author(s) Subjects Instruments Tentative validity implications
1987 Mueser & Butler 
(11)
n = 36 
(5 PTSD-SP; 31 PTSD)
US male veterans; inpatients
Structured interview; MMPI; 
CES
PTSD-SP associated with Hispanic-American ethnicity and 
combat exposure; PTSD-SP is refractory to treatment
1991 Wilcox et al. (12) n = 59
(PTSD-SP fraction not specified)
US male veterans; outpatients
Clinical interview;
Chart review
Hispanic-American ethnicity associated with PTSD-SP
Age of combat, length of exposure to combat, age of onset 
of PTSD not significantly related to the occurrence of auditory 
hallucinations
1996 Butler et al. (13) n  = 38 
(20 PTSD; 18 no PTSD)
US male veterans & non-patient cohort.
All: non treatment-seeking population
Clinical interview; M-PTSD; 
VCER; SADS-C; SANS; 
SAPS
Incidence of psychotic features in PTSD is higher than incidence in 
population without PTSD
1997 Hamner (14) n = 25
(9 PTSD-SP; 16 PTSD)
US male veterans; outpatients
SCID-III-R-P; CAPS; IES Psychotic features do not reflect severity of PTSD-symptoms
PTSD-SP not associated with impact of events
Psychotic features: visual/auditive hallucinations and/or delusions, 
no formal thought disorder
1998 Hamner & Gold 
(15)
n = 41
(6 PTSD-SP; 13 PTSD; 22 healthy controls)
US male veterans; in- and outpatients
SCID-P; CAPS; HRDS; IES PTSD-SP is biologically different from PTSD and normal controls
Dopamine β-hydroxylase is a biological ‘marker’ for PTSD-SP
1999 David et al. (16) n = 53
(21 PTSD-SP; 32 PTSD)
US male veterans; Inpatients
SCID-III-R; clinical 
interviews; M-PTSD; DES
PTSD-SP associated with major depression and minority status.
no association with alcohol/drug abuse
no association with severity of PTSD; no association with 
dissociation
1999 Hamner et al. (17) n = 45
(22 PTSD-SP; 23 PTSD)
US male veterans; Outpatients
SCID-P; CAPS; HDRS; 
PANSS
Psychotic features in PTSD also present in patients without major 
depressive disorder. However strong association between PTSD-
SP and major depressive disorder. PTSD-SP not associated with 
alcohol or drug abuse.
1999 Sautter et al. (18) n = 62
(24 PTSD-SP; 22 PTSD; 16 psychotic no PTSD)
US male veterans;
PTSD and PTSD-SP: outpatients
Psychotic group without PTSD: inpatients
SCID-IV; CES; M-PTSD; 
PANSS; PFAV; QLS
PTSD-SP: higher levels of psychopathology than PTSD or 
psychosis.
Psychotic features in PTSD-SP not related to combat exposure
African-American increased risk for PTSD-SP.
Alcohol/drug dependence doesn’t explain psychotic features in 
PTSD-SP
2000 Hamner et al. (19) n = 80
(40 PTSD-SP; 40 schizophrenia)
PTSD-SP: US male veterans; outpatients
SCID-P;CAPS; PANSS PTSD-SP: less severe delusions and less conceptual 
disorganization and higher rating for ‘hostility’
2000 Ivezic et al. (20) n = 41
(8 PTSD-SP ; 33 PTSD)
Croatian war veterans
(1 female); inpatients
SCID-IV; SADS-L PTSD-SP is highly associated with major depressive disorder. No 
association with personality disorder
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Table 1   Continued
Year Author(s) Subjects Instruments Tentative validity implications
2002 Frueh et al. (21) n = 53 
(23 Afro-Americans; 30 Caucasians)
US veterans (sex not mentioned; outpatients
CAPS; SCID-P, MMPI-2; 
BDI; M-PTSD; DES
Afro-American ethnicity risk factor for PTSD-SP




Clin. interview CAPS; MMPI-
2; BDI; DES; M-PTSD
Ethnicity possible risk factor for development of PTSD-SP
2002 Sautter et al. (23) n = 54 
(23 PTSD-SP; 16 PTSD; 15 healthy matched controls) 
PTSD-SP & PTSD group: US veterans, sex not stated
In- / outpatients: not stated
SCID-IV; FIGS; PTSD-SP is associated with family history of  major depression but 
not with higher rates of psychosis among relatives.
No increased prevalence of psychotic disorders in first-degree 
relatives of patients with PTSD-SP.
2003 Hamner et al. (24) n = 37 
(All PTSD-SP: 19 risperidone, 18 placebo)
US male veterans
In- / outpatients: not stated
SCID-P; PANSS; CAPS; 
HAM-D
Positive and negative psychotic symptoms in PTSD seem to be 
much more ‘refractory’ on risperidone treatment compared to 
improvement of these symptoms in patients with schizophrenia
2003 Cerbone et al. (25) n = 43
(14 PTSD-SP; 14 schizophrenia; 15 controls)
PTSD-SP: US patients with combat related PTSD, males
In- / outpatients: not stated
SCID-IV Suggests that neurobiological abnormalities in PTSD-SP patients 
differ from schizophrenic patients
2003 Sautter et al. (26) n = 29
(13 PTSD-SP; 8 PTSD; 8 controls)
US male veterans
Outpatients
SCID-IV Suggests that PTSD-SP is a severe subtype of PTSD
2004 Pivac et al. (27) n = 55
(All PTSD-SP: 28 olanzapine, 27 fluphenazine)
male war veterans
inpatients
SCID-IV ; WPQ ; PANSS ; 
CGI-S; CGI-I ; PGI-I ; 
DIEPSS
Fluphenazine and olanzapine reduced psychotic and PTSD 
symptoms in PTSD-SP
2004 Kaye (28) n = 300
(56 PTSD-SP; 244 PTSD)
US civilian outpatients, males and females
SCID-IV ; CGI ; GAF No significant differences in risk factors.
PTSD-SP: poorer outcome compared to PTSD
2005 Kozaric-Kovacic & 
Borovecki (29)
n = 969




Psychotic symptoms more often found in patients without 
personality disorders




All male Croatian war veterans
Inpatients
SCID ; CAPS ; PTSD-I ; 
HAM-D ; PANSS
Risperidone reduced psychotic and PTSD symptoms in PTSD-SP
2006 Pivac et al. (31) n = 274




SCID; CAPS; PANSS; 
HAM-D
Platelet serotonin concentration is increased in PTSD-SP 
compared to veterans with or without PTSD or to control subjects.
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symptoms. However, this may be due to the difficulty to differentiate between negative 
symptoms in schizophrenia and avoidance symptoms in PTSD (19).
 It is obvious that PTSD can develop after the onset of schizophrenia. This psy-
chopathological status is known as ‘post-psychotic PTSD’ (PP-PTSD). It is due to 
psychotic phenomena, experienced as traumatic by patients, or due to other 
traumatic events like rape, assault, or witnessing violence or traumatic events during 
forced admissions and treatment (35-39). Patients suffering from PP-PTSD can be 
distinguished from PTSD-SP by the fact that in PP-PTSD the psychotic features 
clearly precede the occurrence of PTSD. 
 Affective disorders. Co-morbidity of major depressive disorder and PTSD ranges 
from 44 to 84%, and co-morbidity between major depressive disorder and PTSD-SP 
is probably even higher (20, 40, 41). Therefore, the question arises whether the 
psychotic features in patients suffering from both depressive disorder and PTSD 
should be attributed to the depressive disorder (depressive disorder with psychotic 
features and co-morbid PTSD) or to the PTSD (depressive disorder and co-morbid 
PTSD-SP). A strong correlation was found between the severity of PTSD symptoms 
and the severity of depressive symptoms in PTSD-SP patients, as well as significantly 
higher PANSS-ratings of psychosis in PTSD-SP patients with major depressive 
disorder compared to PTSD-SP patients without a co-occurring major depressive 
psychosis do exist (excluded in this review). This and the preponderance of studies 
on war veterans could lead to a biased age of onset.
 Prevalence. No epidemiological data are available. Frequency rates of psychotic 
symptoms in patients diagnosed with PTSD vary between 15% and 64% in patients 
with PTSD (20) primarily depending on sampling strategies. 
Delineation
To what extent can PTSD-SP be differentiated from other psychiatric syndromes?
 Schizophrenia. Within current nosological classification systems, patients 
presenting with PTSD-SP would be classified as suffering from schizophrenia and 
co-morbid PTSD. However, there are differences in symptomatology between 
patients with PTSD-SP and schizophrenia. The content of hallucinations in PTSD-SP 
patients is almost always trauma-related, but often accompanied by non-trauma-re-
lated content (17, 19). Delusions in PTSD-SP patients are mainly paranoid and 
persecutory in nature, whereas in schizophrenia the delusions are often more 
complex and bizarre. Formal thought disorders (e.g. loose associations, incoherence, 
neologisms) are quite common in schizophrenia, but exceptional in PTSD-SP (19). 
There are no disturbances of affect (e.g. inappropriate) in PTSD-SP patients. No dif-
ferentiation can be made between PTSD-SP and schizophrenia in terms of negative 
Table 1   Continued
Year Author(s) Subjects Instruments Tentative validity implications
2007 Kastelan (32) n = 91
(All PTSD)
Male war veterans
SCID; CAPS; HTQ Severity of hyperarousal symptoms was positively correlated with 
occurrence of psychotic symptoms




CAPS, CGI-I, CGI-S, 
PANSS, DIEPSS
Quetiapine reduced psychotic and PTSD symptoms in PTSD-SP
2007 Pivac et al. (34) n = 386
(28 PTSD-SP; 78 PTSD; 41 exposed vets without PTSD; 
242 healthy controls)
All Croatian males
SCID; CAPS; PANSS; 
HAM-D
Higher platelet MAO-B activity in PTSD-SP compared to non-
psychotic PTSD, Vets without PTSD and healthy controls
BDI: Beck Depression Inventory; CAPS: Clinician Administered PTSD Scale; CES: Combat Exposure 
Scale; CGI: Clinical Global Impression Scale; CGI-S: Clinical Global Impression Severity Scale; CGI-I: 
Clinical Global Impression Improvement Scale; DES: Dissociative Experience Scale; DIEPSS: Drug 
Induced Extra-Pyramidal Symptoms Scale; FIGS: Family Interview for Genetic Studies; GAF: Global 
Assessment of Functioning; HAM-D: Hamilton Depression rating scale; IES: Impact of Events Scale; 
MMPI-2: Minnesota Multiphasic Personality Inventory-2; M-PTSD: Mississippi scale for Combat-Related 
Posttraumatic stress disorder; PTSD-I: PTSD Interview; PANSS: Positive and Negative Syndrome
Scale; PFAV: Past Feelings and Acts of violence Scale; PGI-I: Patient Global Impression Improvement 
Scale; QLS: Quality of Life Scale; SADS-C: Schedule for Affective Disorders and Schizophrenia – 
Change Version; SADS-L: Schedule for Affective Disorder and Schizophrenia – Lifetime Version; SANS: 
Scale for the Assessment of Negative Symptoms; SAPS: Scale for the Assessment of Positive 
Symptoms; SCID-III-R-P: Structured Clinical interview for DSM-III-R with psychotic screen; SCID-IV: 
Structured Clinical Interview for DSM-IV ; VCER: Vietnam Combat Exposure Scale; WPQ: Watson’s 
PTSD questionnaire.
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‘general psychopathology’ subscale of the PANSS. The scores on the positive and 
negative syndrome subscales in the risperidone group did not decrease significantly 
more than the scores in the placebo group. Two studies (uncontrolled pre-post 
comparisons: n=26 and n=53) reported a significant improvement on risperidone as 
well as quetiapine mono-therapy (30, 33). The fourth study compared olanzapine 
(n=28) and fluphenazine (n=27) as a mono-therapy in PTSD-SP patients in a six-week 
open trial (27). Compared to fluphenazine, olanzapine showed significantly (p<0.05) 
more improvement in negative symptoms and general psychopathology of the 
PANSS and in PTSD symptoms. These findings are consistent with a subtype of 
schizophrenia, or postpsychotic PTSD, or with a specific kind of affective disorder 
with psychotic symptoms as well as with PTSD-SP as a separate diagnostic entity.
 Psychotherapy. No systematic empirical research on this topic was found. 
Family studies
Does PTSD-SP run in families?
No studies have been performed to detect the prevalence or incidence of PTSD-SP 
in relatives of patients suffering from PTSD-SP. One study focused on familial 
vulnerability to schizophrenia and other psychoses in first degree relatives of PTSD-SP 
patients. The study showed an increased prevalence of major depression, but no 
increased prevalence of psychotic disorders in first degree relatives (23). First degree 
relatives of PTSD-SP probands (as well as of PTSD probands) are at higher risk for 
depressive disorder, compared to healthy controls: Thirteen relatives (15,9%) of 
PTSD-SP patients and 18 relatives of PTSD-SP patients (15,9%) were diagnosed with 
major depression, compared to three relatives (4.8%) of the healthy comparison 
probands (p=0.01) (23). 
Biological correlates/laboratory studies
Are there biological correlates/laboratory measures that can be used as external 
validators for PTSD-SP?
 Significantly (p<0.01) elevated plasma dopamine beta-hydroxylase (DβH) 
activity has been observed in patients suffering from PTSD-SP (n=6) compared to 
patients with PTSD without psychotic features (n=13) as well as compared to normal 
controls (n=22) (15). In addition, cerebrospinal fluid concentrations of corticotropin-
releasing factor (CRF) in PTSD-SP patients (n=13) has been shown to be significantly 
higher (p<0.01) compared to patients with PTSD without psychotic features (n=8) 
and healthy controls (n=8) (26). 
 Furthermore, Pivac et al. (34) observed increased levels of blood platelet 
monoamine oxidase B activity (MAO-B) in PTSD-SP war veterans compared to 
non-psychotic veterans with or without PTSD and healthy control subjects. In another 
study increased blood platelet-levels of serotonine (5-HT) activity were identified as 
disorder (17). This finding suggests that PTSD, depressive disorder and psychotic 
features are somehow interconnected in patients suffering from PTSD-SP. It remains 
unclear, however, to what extent psychotic features in PTSD-SP can be explained by 
the co-morbid depressive disorder since a considerable portion of PTSD-SP patients 
do not have major depressive disorder. In one study 68% of all patients with PTSD-SP 
had a co-morbid depressive disorder, indicating that in at least 32% of the patients in 
this study the presence of psychotic features cannot be explained by the co-morbid 
depressive disorder (17). In an inpatient population of PTSD-SP patients, a significant 
association (p<0.02) was found between the presence of psychotic features and the 
presence of major depressive disorder, while none of these patients met the 
diagnostic criteria of depressive disorder with psychotic features (16, 42). A large 
scale study shows that patients suffering from a depressive disorder with psychotic 
features were almost four times more likely to suffer from co-morbid PTSD, compared 
to patients with a non-psychotic depression: 58% versus 16% (43). In another study, 
however, all depressive disorders with psychotic features were preceded by PTSD 
(44). 
 Dissociative disorders. The only study looking at comorbid dissociative disorders 
did not find a relationship between psychotic symptoms and dissociative features in 
patients with PTSD, as measured by the Dissociative Experience Scale (DES) (16). 
 Alcohol/drugs dependency/abuse. No relationships were found between psychotic 
features in PTSD and alcohol or drug dependence, nor were the psychotic features 
related to intoxication or withdrawal (11, 12, 16, 17). 
Course
Has PTSD-SP a typical course, i.e. a course that differs from that of PTSD, 
schizophrenia or psychotic depression?
 No study that meets the necessary basic requirements of this review has been 
conducted on this specific topic. 
Treatment response
Are there treatment-effects that are typical for PTSD-SP?
 Pharmacotherapy. Differences in drug effects can indicate the presence of 
distinct pathophysiological processes and hence add support to the validity of a 
nosological entity (45). Recently, the results of four trials have been published. The 
first is a randomised controlled trial in which risperidone (n=19) or placebo (n=18) 
were added to the already prescribed medications (mainly antidepressants) in 
combat veterans with PTSD-SP (24). This study showed that after six weeks of 
treatment the composite score on the Positive and Negative Syndrome Scale 
(PANSS) decreased significantly more from baseline in the risperidone group, 
compared to placebo group (p<0.05). This effect was due to a decrease in the 
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 Patients suffering from PTSD-SP often suffer from a depressive disorder as well. 
It is still unclear whether the psychotic features should be interpreted as part of a 
PTSD (i.e. PTSD-SP with a co-morbid depressive disorder) or as part of a depressive 
disorder (i.e. PTSD with a co-morbid depressive disorder with psychotic features). 
The increased dopamine beta-hydroxylase (DβH) activity in PTSD-SP patients favors 
the first explanation, since DBH activity is decreased in patients with a depressive 
disorder with psychotic features. However the study that found an increased DBH in 
PTSD-SP patients did not control for the presence of a co-morbid depressive 
disorder. 
 Studies clearly differentiating personality disorders, especially borderline personality 
disorder, from PTSD-SP are lacking.
No sound data are available on the clinical course of PTSD-SP. A few studies with a 
lower evidence level than three briefly touch upon the course of PTSD-SP. Two studies 
mention that PTSD-SP is a chronic condition without providing more specific empirical 
data (46-48). PTSD-SP differs from disorders like (brief) reactive psychosis or acute 
transient psychotic disorder due to a different course: in PTSD-SP posttraumatic 
stress disorder develops first and in a later stage psychotic features follow and 
become chronic.
 Psychotic features in PTSD-SP, especially hallucinations, could be confused with 
dissociative features. Instruments like the MMPI-2 fail to differentiate adequately 
between dissociative and psychotic features in PTSD. One study did not find a 
dissociative disorder in patients with PTSD-SP and no association was found between 
PTSD-SP and DES-scores.
 Sound data on psychotherapy and PTSD-SP are missing. One study describes 
a day hospital program for PTSD-SP patients, using trauma focus groups including 
graduated therapeutic exposure, cognitive restructuring, and relapse prevention (49). 
At the end of the program 70% of the patients reported greater control over PTSD 
symptoms, compared to the start of the treatment. However, this study did not use 
objective outcome measures and hence did not meet the minimal requirements for 
inclusion in this review.
 Summarizing the reviewed studies, PTSD-SP is emerging as a syndrome that 
consists of posttraumatic stress disorder, joined by one or more psychotic features, 
especially hallucinations and delusions. The prevalence of PTSD-SP is unclear with 
varying rates in mental treatment seeking populations (15-64%). The psychotic 
features are not confined to episodes of re-experiencing, but remain present 
continuously. The content of these psychotic features is generally paranoid in nature, 
and no first rank Schneiderian psychotic features appear to be present. There is no 
history of psychotic episodes prior to the traumatic event(s). No relationship has been 
found between the nature or severity of the traumatic events and the presence of 
PTSD-SP. In first degree relatives there is an increased prevalence of major depression 
well, in PTSD-SP war veterans compared to war veterans with or without PTSD and 
healthy control subjects (31). 
 Finally, PTSD-SP is associated with smooth pursuit eye movement (SPEM) 
deficits that are qualitatively different from SPEM-deficits of patients suffering from 
schizophrenia as well as healthy controls: PTSD-SP patients (n=14) are deficient in 
higher velocity SPEM as compared to patients suffering from schizophrenia (n=14), 
and schizophrenia is associated with lower velocity SPEM deficits than healthy 
controls (n=15) (25). 
Discussion
It seems likely that PTSD-SP is distinct from schizophrenia, because there is no 
increased prevalence of psychotic disorders in first degree relatives, and because 
SPEM-deficits differ qualitatively from those seen in schizophrenia. Several (pre-post 
design) studies show a positive response of psychotic symptoms to neuroleptics in 
PTSD-SP. However in the only available RCT, delusions and hallucinations did not 
improve more with risperidone than with placebo, which would be expected in cases 
of schizophrenia. As to the phenomenology, there are clear differences between 
PTSD-SP and schizophrenia, although, the clinical description of PTSD-SP still shows 
some inconsistencies. In early studies, PTSD patients were described with merely 
auditory hallucinations as psychotic symptoms. In later studies delusions and 
negative psychotic features were depicted as well. Several studies show that 
co-morbid disorders like alcohol- or drug related disorders (which could give rise to 
positive psychotic symptoms) cannot account for the presence of the psychotic 
features in PTSD-SP.
Table 2   Number of studies with at least level three evidence (minimal requirement 
case-control studies) addressing specific validity criteria
Validity criteria Number of studies
1 Clinical description 11
2 Delineation 9
3 Course 0
4 Treatment response 3
5 Family studies 1
6 Biological correlates/laboratory studies 5
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leading to further research into specific interventions for this complex, severe and 
often chronic disorder. Special attention is warranted for research in other samples 
than male combat veterans, and research addressing the issue of differentiating 
PTSD-SP from depressive disorder with psychotic features. Additional studies are 
also needed that focus on co-morbid personality disorder (borderline, schizotypal, 
paranoid), the course of PTSD-SP, biological correlates and etiological factors.
(like in PTSD) but no increased prevalence of psychotic disorders (which would be 
expected in cases of schizophrenia). Positive correlations have been found in 
PTSD-SP patients with ethnicity (African-American and Hispanic), with co-morbid 
depressive disorder, with the enzyme-activity of DBH and with cerebrospinal fluid 
concentrations of CRF, blood platelet serotonine and MAO B activity. There are 
specific smooth pursuit eye movement deficits. General psychopathology improves 
on adjunctive risperidone treatment, positive and negative psychotic symptoms do 
respond in uncontrolled pre-post comparisons but not significantly compared to 
placebo in another study. Olanzapine treatment resulted in larger reductions in 
negative symptoms and PTSD symptoms than fluphenazine.
 Most of the included studies have limitations. First, most studies focus on U.S. 
combat veterans, and very few data are available on female subjects. Second, a 
recurrent finding is the increased incidence of PTSD-SP among African-Americans 
and Hispanic Americans combat vets. This might be a research artifact since none of 
the applied research instruments have been cross-culturally validated. Therefore the 
question is still unresolved whether ‘ethnicity’ or racial group affiliation are risk factors 
for developing PTSD-SP, or whether certain ethnic groups have higher scores on 
items indicating psychosis due to measurement bias. Third, studies offering biological 
evidence for the validity of PTSD-SP have not been replicated. Finally, no research on 
co-existing personality disorders (especially borderline personality disorder) in 
PTSD-SP exists to elucidate the relationship between psychotic features occurring in 
PTSD and the presence of a severe personality disorder.
Based on the available studies we propose the following criteria for PTSD-SP, as a 
provisional diagnostic entity:
1. DSM-IV TR criteria of PTSD
2. positive psychotic symptoms such as delusions and/or hallucinations
3. Psychotic features are not confined exclusively to episodes of re-experiencing or 
flashbacks and should be distinguished from DSM IV-TR PTSD-criterion B3: 
“acting or feeling as if the traumatic event were recurring (includes a sense of 
reliving the experience, illusions, hallucinations, and dissociative flashback 
episodes)” (50, p. 468).
4. no formal thought disorder
5. no brief psychotic disorder
6. PTSD precedes the onset of psychotic features
7. no history of psychotic episodes prior to the traumatic event(s) 
Although the abovementioned criteria for PTSD-SP are not yet fully validated, the 
reviewed studies offer ample indications for further inquiry. Additional research focusing 
on the validity of PTSD-SP is needed, not for the sake of adding another nosological 
subtype to DSM-IV or ICD-10, but to gain a clearer picture of this group of patients 
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Introduction
A number of publications express the emergence of a new syndrome: posttraumatic 
stress disorder with secondary psychotic symptoms (PTSD-SP). This syndrome 
meets DSM-IV TR criteria of posttraumatic stress disorder, followed by psychotic 
features, especially hallucinations and delusions. These features are not confined to 
episodes of re-experiencing. The content of these psychotic features is often trauma-
related, paranoid in nature, and not bizarre. There is no formal thought disorder. 
PTSD-SP appears to have a chronic course. Comorbid major depressive disorder 
occurs frequently. There is no history of psychotic episodes, prior to the traumatic 
event(s). No relationship has been found between the nature or the severity of the 
traumatic events and the subsequent manifestation of psychotic features in patients 
suffering from PTSD. In first degree relatives there is an increased prevalence of 
major depression, but not of psychotic disorders. Prevalence rates of PTSD-SP varies 
considerably between studies (from 15% to 64%), primarily depending on sampling 
strategies used. The prevalence rate in the general population is unknown (1). 
 In this paper all studies on this topic are reviewed to determine the state of 
 neurobiological knowledge on this potential syndrome and its pathophysiological 
underpinnings. The main findings of these studies are reported as well as the varied 
spectrum of hypotheses put forward.
Methodology
Studies published between 1980 and 2006 were traced using the databases 
MEDLINE, PsycINFO, EMBASE Psychiatry, and Published International Literature On 
Traumatic Stress (PILOTS), with the full-text terms: ‘PTSD’, ‘posttraumatic stress 
disorder’, ‘stress disorders, posttraumatic’, ‘psychological trauma’, each combined 
with ‘psychosis’, ‘psychotic’, ‘schizophrenia’, ‘hallucination’, ‘hallucinations’, ‘delusion’, 
‘delusions’, and ‘reality testing’. Publications were screened, using the title and the 
abstract for relevance to the topic, i.e. PTSD and psychotic features. Reference lists 
were screened to find additional studies.
Results
A total of 45 publications were detected dealing with adult patients suffering from 
PTSD-SP. Only nine out of these studies focused on neurobiological issues and 
surpassed the evidence level of case studies; five are mainly psychopharmacologi-
cally oriented. The main findings (summarized in table 1) concern corticotrophin 
Abstract
The neurobiological knowledge on the potentially new diagnostic entity “posttraumatic 
stress disorder with secondary psychotic features” (PTSD-SP) is reviewed. Studies 
published between 1980 and 2006 were traced focussing on adult patients suffering 
from this “syndrome”. Studies on cortisol, corticotrophin releasing hormone, 
dopamine beta-hydroxylase, smooth pursuit eye movements and psychopharmacol-
ogy are described and potential pathophysiological mechanisms briefly discussed. 
The results of this study corroborate preliminary phenomenological evidence that 
PTSD-SP can be delineated from other related disorders like schizophrenia, PTSD 
and, depressive disorder with psychotic features. More research is needed to validate 
the nosological status of PTSD-SP in order to promote neurobiological research and 
adequate therapeutic interventions.
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velocity SPEM. PTSD-SP subjects showed deficits in the continuation of smooth 
pursuit, while schizophrenia was associated with deficits in the initiation of smooth 
pursuit.
Pharmacotherapy
Only one of the available pharmacological studies on PTSD-SP meets an adequate 
methodological quality, i.e. a randomized, double-blind, placebo-controlled trial. In 
this study risperidone or placebo were added to a standard regimen of antidepressant 
treatment (9). The risperidone group improved significantly more than the placebo 
group in terms of  the total Positive and Negative Syndrome Scale (PANSS). A more 
detailed analysis revealed that the level of significance was reached due to the 
improvement of the ‘general psychopathology subscale’ of the PANSS. Neither the 
‘positive symptoms subscale’ nor the ‘negative symptoms subscale’ of the PANSS 
improved significantly. Thus, while general psychopathological symptoms improved, 
positive symptoms like delusions and hallucinations improved to the same degree in 
both groups. 
releasing hormone (CRH) plasma levels of cortisol, dopamine beta-hydroxylase 
(DβH), smooth pursuit eye movement (SPEM) and pharmacotherapy.
Corticotrophin releasing hormone
Based on the assumption that PTSD-SP could be a severe subtype of PTSD, 
enhanced hyperactivity of the CRH system can be expected. Therefore, Sautter et al. 
assessed the cerebrospinal fluid concentrations of CRH (2). Their results demonstrate 
that patients with primary PTSD and subsequent appearing psychotic symptoms 
have higher cerebrospinal fluid concentrations of CRH than patients suffering from 
PTSD without psychosis and healthy comparison subjects. 
Cortisol
Abnormal cortisol levels have been found in a wide array of psychiatric disorders, 
including psychosis, PTSD and depressive disorders. Manguno-Mire et al. (3) 
demonstrate that subjects with PTSD and secondary psychotic features show 
significantly higher baseline cortisol levels than subjects with PTSD without psychotic 
features and control subjects. In contrast to the non-suppression associated with 
major depressive disorder with psychotic features (4), PTSD-SP subjects show 
 hypersuppression of cortisol following 1 mg of dexamethasone admission. This 
study indicates that PTSD-SP has a neuroendocrine profile different from PTSD and 
depressive disorder with psychotic features. 
Dopamine beta-hydroxylase
DβH converts dopamine into norepinephrine. During synaptic transmitter release it 
enters the extracellular space and hence becomes present in the cerebrospinal fluid 
and in blood plasma. DβH activity in plasma is a very stable heritable trait but varies 
extensively across unrelated individuals (5). Hamner and Gold (6) observed that 
plasma DβH -activity was elevated in PTSD patients with psychotic features as 
compared to both PTSD patients without psychotic features and healthy control 
subjects.
Smooth pursuit eye movement 
SPEM refers to the movement of the eye that smoothly tracks slowly moving objects 
in the visual field. SPEM deficits are a well established phenomenon in schizophrenia 
(7). Cerbone et al. (8) studied SPEM in patients suffering from PTSD-SP and found 
marked differences compared to schizophrenia. The performance of patients with 
PTSD and secondary psychotic symptoms differed significantly from controls and 
from patients with schizophrenia in terms of the percentage of time in smooth pursuit. 
Patients with PTSD-SP showed impaired SPEM performance at higher velocity as 
compared to normal controls, while schizophrenia subjects were deficient in low 
Table 1   Summary of findings
PTSD PTSD-SP Schizophrenia
Baseline cortisol 
(Manguno-Mire et al., in prep.)
=  *) ↑ *)
CRH in CSF
(Sautter et al., 2003)
=  *) ↑ *)
Plasma DβH
(Hamner and Gold, 1998)
=  *) ­↑ *)
SPEM performance











(Hamner et al., 2003)
Positive psychotic 
features do not 
improve **)
*)  compared to healthy controls; **) compared to placebo
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of this complex disorder. Neurobiological studies focusing on PTSD-SP are limited. 
Nonetheless, the divergent topics, and the PTSD-SP specific findings of these 
studies, strengthen preliminary phenomenological evidence that PTSD-SP can be 
delineated from other related disorders like schizophrenia (differences in smooth 
pursuit and DβH), PTSD (differences in DβH and cerebrospinal fluid levels of CRH) as 
well as depressive disorder with psychotic features (differences in DβH activity). 
Abbreviations
cAMP cyclic adenosine monophosphate
CRH Corticotrophin releasing hormone
DβH Dopamine beta-hydroxylase
DSM-IV TR Diagnostic and Statistical Manual of Mental Disorders, Text Revision
HPA-axis hypothalamus-pituitary-adrenal axis
PANSS Positive and Negative Syndrome Scale
PILOTS Published International Literature On Traumatic Stress
PTSD Posttraumatic stress disorder
PTSD-SP Posttraumatic stress disorder with secondary psychotic features
SPEM Smooth pursuit eye movement
Pathophysiological hypotheses
A variety of pathophysiological hypotheses on PTSD-SP have been proposed in the 
abovementioned studies. Sautter et al (2) proposed several hypotheses based on 
increased activation of CRH-circuitry:
1. Increased activation of hypothalamic CRH would produce increased cortisol 
secretion from the adrenal gland, which in turn increases CNS dopamine-activity 
of the meso-cortical dopamine system. 
2. Higher levels of CRH could lead to psychotic symptoms through the mechanism 
of CRH at the cyclic adenosine monophosphate (cAMP) level in the frontal 
cortex: High levels of CRH in PTSD-SP augment dopaminergic stimulation of 
cyclic AMP in the frontal cortex because both CRH receptor subtypes use 
G-protein stimulatory heterotrimeric receptors that increase cyclic AMP levels 
when activated by CRH.
3. Activation of CRH systems located outside the HPA-axis (e.g. locus coeruleus, 
amygdalae and the hippocampus) could, due to an increased frontal circuit 
dopamine activity, result in increased secretion of CRH in PTSD-SP subjects.
4. Another hypothesis, not based on dopaminergic activity, but on noradrenergic 
hyperactivity has been proposed by Hamner and Gold (6): Higher dopamine 
beta-hydroxylase activity could be expected to facilitate increased noradrenaline 
synthesis and might contribute to psychosis.
Discussion
There is ample evidence that stress and cortisol are involved in dopaminergic 
alterations in the brain and that hypercortisolemia as in M. Cushing can lead to frank 
psychosis. Thus a dopamine-based pathophysiology is worthwhile exploring 
although the lack of antipsychotic activity of risperidone points towards a pathophys-
iological mechanism that is (at least partially) different from the one proposed in 
schizophrenia. The altered cortisol and CRH levels also indicate a (partially) different 
pathophysiological mechanism operating in PTSD-SP compared to PTSD and 
depressive disorder with psychotic features. 
 It should be noted that all published research findings await replication and the 
presented findings should, therefore, be met with caution and reliable pathophysio-
logical hypotheses are still preliminary. Finally no direct comparison data exist 
comparing PTSD-SP with major depressive disorder with psychotic features.
 Research focusing on the validation of PTSD-SP and the delineation of clear 
diagnostic criteria is of great importance for the promotion of neurobiological and 
pathophysiological research and the study of (pharmaco-) therapeutic interventions 
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Introduction
Clinical and epidemiological studies have reported high rates of psychotic features in 
patients suffering from posttraumatic stress disorder (PTSD) (1-3). Psychotic  features 
are present in up to 40% of patients with combat-related PTSD (4). In these patients, 
chronic hallucinations and delusions that are not limited to flashback episodes are 
most prominent (5). Frequently these patients meet DSM-IV criteria of schizophrenia 
(6-9). However, according to several authors, these patients do not suffer from 
schizophrenia (1, 10) and a separate diagnostic category has been suggested that is 
distinct from schizophrenia: psychotic posttraumatic stress disorder (2, 3, 10, 11). 
This suggestion led to the present study in which we compare the clinical features of 
patients with schizophrenia and patients with psychotic PTSD in order to answer the 
question whether or not these patients represent two distinct diagnostic entities. 
Previous studies on this topic were limited to male war veterans exposed to 
combat-related trauma (2). In this study we focus on a different and more diverse 
population: a multi-ethnic sample of refugees, both male and female, who have been 
exposed to a wide range of traumas, not exclusively combat-related. To our 
knowledge, this is the first study to address this question in a multi-ethnic refugee 
population. The main objective in this study is to search for similarities and differences 
in core clinical features of psychosis and trauma history in patients with schizophrenia 
and patients with posttraumatic stress disorder. Previous studies focusing on 
psychosis and PTSD were based on lifetime prevalence rates of PTSD, psychosis 
and other comorbid conditions and did not take into account the temporal 
relationships between these conditions (3, 12-14). The present study focuses on the 
temporal relationship between PTSD and psychotic symptoms. In contrast to previous 
studies we make a clear distinction between patients who developed a chronic 
psychotic disorder without preceding PTSD and patients who experienced traumatic 
events, developed PTSD and subsequently became chronically psychotic. This latter 
group of patients we will, from now on, identify as suffering from ‘posttraumatic stress 
disorder with secondary psychotic features’ (PTSD-SP).
 In this study, we first compare the group of PTSD-SP patients (i.e. psychotic 
patients with a diagnosis of PTSD before the onset of the first psychotic episode) with 
a group of patients suffering from schizophrenia (i.e. psychotic patients without a 
diagnosis of PTSD or with an onset of PTSD after the onset of the first psychotic 
episode) regarding to the type and severity of psychotic features, the presence of 
comorbid disorders, clinical course, and experienced traumatic events. In addition, 
we explore whether PTSD-SP patients with a formal DSM-IV diagnosis of schizophrenia 
can be distinguished from PTSD-SP patients without a formal DSM-IV diagnosis of 
schizophrenia and whether these PTSD-SP subgroups can be distinguished from 
patient s with schizophrenia (i.e. psychotic patients without a diagnosis of PTSD or 
Abstract 
The aim of this study was to evaluate whether chronic psychosis in ‘posttraumatic 
stress disorder with secondary psychotic features’ (PTSD-SP) can be distinguished 
from psychosis in schizophrenia by clinical features and trauma history. In a cross 
sectional study among refugees, inpatients with PTSD-SP were compared to 
inpatients suffering from schizophrenia. Main diagnosis and comorbid disorders 
were assessed as well as detailed clinical features and trauma history. Positive 
psychotic symptoms were equally present in both groups, except for conceptual dis-
organization which was less prevalent in the PTSD-SP group. Compared to the 
schizophrenia group, patients with PTSD-SP reported markedly fewer negative 
symptoms, less lack of judgment and insight, much higher levels of anxiety and 
depression, and more comorbid psychiatric disorders. 
 It is concluded that PTSD-SP can be distinguished from schizophrenia by clinical 
features. These findings suggest that PTSD-SP is clinically different from schizophrenia 
and support previous proposals to conceptualize PTSD-SP as a separate nosological 
entity in DSM-5.
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Symptom Measures
In both groups (PTSD-SP and schizophrenia) we assessed current psychotic 
symptoms with the Positive and Negative Syndrome Scale (PANSS) (18) and the 
psychotic symptom rating scale (PSYRATS) (19). The Hopkins Symptoms Checklist 
(HSCL-25) (20) was used to assess the presence and severity of current anxiety and 
depressive symptoms. The experienced traumatic events were measured with the 
trauma scale of the Harvard Trauma Questionnaire (HTQ) which contains a traumatic 
events scale specifically designed for trauma’s experienced by adult refugees (21). 
All symptom measures were administered by interviewers that were blind for 
diagnostic group status. Professional interpreters assisted in 80% of all interviews. 
The HTQ and HSCL-25 have proven cross-cultural reliability and validity for the 
groups under study (22). In that study, different translations of those scales were 
assessed and the Cronbach’s internal consistency (alpha) was used as a measure of 
reliability. Cronbach’s alpha was high, ranging between 0.8 and 0.9 across the 
different scales and language versions. Validity was assessed by item-total scale 
correlations. A few items with low item-total scale correlations were identified but their 
effect on the total scores were small.
Statistical analysis 
Variables were tested for normal distribution and homogeneity of variance. All tests 
were two-sided and p-values < 0.05 were considered significant. If appropriate, 
 Bonferroni-corrections were applied and effect sizes were computed and added. 
Group differences were tested using t-tests for continuous variables and chi square 
tests or Fisher’s exact tests for categorical variables. Logistic regression analysis was 
applied to identify significant and clinically useful independent predictors for diagnostic 
group status. Finally, multivariate analysis (MANOVA) followed by discriminant analysis 
was used to analyse the underlying symptom dimensionality of the diagnostic groups. All 
statistical analyses were performed using PASW Statistics 18.0 for Windows (SPSS/
IBM Inc, Chicago, IL).
Results
Sample characteristics
A total of 150 consecutive inpatient refugees in the two sites were screened for 
eligibility resulting in 51 subjects, meeting all criteria for final assessments and 
including 34 patients with PTSD-SP and 17 patients with schizophrenia (Figure 1). 
with an onset of PTSD after the onset of the first psychotic episode) based on clinical 
characteristics using MANOVA and discriminant analysis.
Methods
Participants and entry criteria
This cross sectional study recruited patients from two mental health hospitals in the 
Netherlands that provide inpatient treatment to refugees, who fled to the Netherlands 
from many parts of the world. Consecutive sampling was applied with recruitment of 
recently admitted patients meeting the following entry criteria: being a refugee, 16 
years or older, and at least one DSM-IV PTSD symptom or at least one psychotic 
symptom according to the clinician. This was a pre-selection, performed  in order not 
to miss any potentially eligible study-participants with PTSD and/or psychotic 
disorders. Subsequent accurate assessment of the diagnosis and final in- or 
exclusion was done with the Schedules for Clinical Assessment in Neuropsychiatry, 
as described in the next paragraph. After complete description of the study to the 
participants, written informed consent was obtained, some together with the patient’s 
representative. All study procedures were approved by the Dutch Mental Health 
Ethical Review Board (METIGG).
Diagnostic assessment and group allocation
Main diagnoses and the presence of comorbid disorders were assessed (both 
‘present state’ and ‘lifetime before’) with the Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN) (15). The SCAN does not enforce diagnosis-driven a priori 
grouping of symptoms and has been shown to be cross-culturally valid and applicable 
(16). We recruited two groups of patients:
1. Similar to Sautter et al (17), we defined the ‘PTSD-SP-group’ as patients with 
DSM-IV PTSD and psychotic symptoms, in whom the onset of PTSD preceded 
the onset of psychosis. We carefully distinguished psychotic symptoms from 
(dissociative) flashback episodes with illusions and hallucinations while reliving 
the experience. These latter symptoms were interpreted as part of the 
conventional DSM-IV diagnostic criteria for PTSD.
2. The ‘schizophrenia group’ was defined as those patients meeting DSM-IV criteria 
of schizophrenia but without preceding DSM-IV PTSD. 
In both groups, patients with bipolar disorder, organic mental disorders and malingering 
were excluded. 
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The two diagnostic groups did not differ significantly on demographic characteris-
tics, except for the geographic region of origin (p=0.016, Fisher’s exact test, Table 1): 
refugees with PTSD-SP came more often from West Asian and in particular from 
South and East European countries, whereas refugees from South and South-East 
Asian were overrepresented in the schizophrenia group.
Clinical features
Table 2 shows a detailed comparison of the PANSS ratings between the PTSD-SP 
and the schizophrenia group. 
Figure 1   Flow chart of study inclusion: subjects with PTSD and secondary 
psychotic features or subjects with schizophrenia without PTSD prior 
to first psychotic episode
Admissions 150
Did not meet entry criteria 29
Eligible 
 (at least one PTSD symptom 
 or at least one psychotic symptom)
121
 Excluded due to short stay (< 2 months) 16
 Unable to test due to organic disorder or mutism 2
 Refused consent 17
Consented and SCAN assessment 86
  Excluded after SCAN assessment due to:  
bipolar disorder (n=4) missing data due  
to incomplete testing (> 2 missing  
symptom measures) (n=3) other diagnoses 
(subtreshold PTSD, n=2) malingering (n=2)
11
75















and if PTSD 
is present its 
onset was after 
the onset of 
first psychotic 
episode
Table 1   Comparison of demographic sample characteristics of the ‘PTSD-SP-












































Age 38.6 9.9 37.6 10.3 49 0.33 1 0.74
Sex 1 - 3 0.46
Male 26 76.5% 15 88.2%
Female 8 23.5% 2 11.8%
Marital status 1 2.56 2 0.11
Married 22 64.7% 7 41.2%
Single 12 35.3% 10 58.8%
Years of education 8.5 4.6 9.4 4.5 49 -0.68 1 0.50
Religion 2 0.15 3 1.00
Islamic 15 44.1% 8 47.1%
Christian 13 38.2% 6 35.3%
Other 6 17.6% 3 17.6%
Region of origin - 9.93 3 0.016
Southern & Eastern Europe 12 35.3% 1 5.9%
Western Asia 9 26.5% 2 11.8%
Southern & South-eastern Asia 5 14.7% 8 47.1%
Africa 8 23.5% 6 35.3%
1) t-test; 2) Chi square test; 3) Fisher’s exact test
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Comorbidity
Patients in the PTSD-SP group had about three times as many comorbid disorders 
as patients in the schizophrenia-group (mean 2.74, SD=2.19 versus 0.94, SD=1.68; 
t=2.96, df=49, p = 0.005), see Table 4.  Hierarchy-free diagnostic algorithms showed 
the same results, indicating that, the comparative paucity of co-morbid disorders in 
the schizophrenia-group was not attributable to this hierarchy. Four of the 17 patients 
in the ‘schizophrenia group’ (23.5%) suffered from PTSD that developed after the 
onset of schizophrenia.
Diagnostic groups did not differ on the PSYRATS ratings except for auditory hallucinations 
These were significantly more severe in the PTSD-SP group (mean=29.1, SD=10.8) 
compared to the schizophrenia group (mean=19.1, SD=14.4) ( t=2.52, df=49, 
p=0.018). This was mainly attributable to the amount of negative content of the voices 
(mean=3.0, SD=1.5 versus mean=1.5, SD=1.5) (t=3.39, df=49, p=0.001), the 
amount of experienced distress caused by voices (mean=3.2, SD=1.3 versus 
mean=1.6, SD=1.6) (t=3.36, df=27.3, p=0.002), and the intensity of experienced 
distress induced by hearing voices (mean=3.1, SD=1.3 versus mean=1.6, SD=1.6) 
(t=3.28, df=26.7, p=0.003). Additional features are presented in Table 3.
 The mean duration between the onset of PTSD and the onset of the psychotic 
disorder in the PTSD-SP group was 4.5 years (SD=6.1). Of these patients 20.6% 
developed psychosis within 6 months after the onset of PTSD, 55.9% developed 
psychosis between 6 months and 5 years, and in 23.5% of the patients psychosis 
started more than 5 years after the onset of PTSD. The mean age of onset of PTSD in 
PTSD-SP patients was around 30 years (SD=12.7 years) of age (median=29 years).








































3.21 0.54 2.14 0.80  5.01 23.54 <0.001 0.72
Severity anxiety 
symptoms (HSCL)
3.26 0.54 1.80 0.76  7.01 23.54 <0.001 0.82
Age of onset of the first 
psychotic episode
34.4 9.9 24.2 9.8  3.46 49   0.001 0.44
Duration of mental 
health care in months 
per year
7.61 4.1 7.63 5.9 -0.19 49   0.98 0.03
Number traumatic 
events (HTQ)
9.8 2.8 5.8 3.1  4.59 49 <0.001 0.55
a:  Effect size R: <0.10 = trivial; 0.10-0.29 = small; 0.30-0.49 = medium; 0.50-0.69 = large;  
>0.70 = very large





Comorbidity  N   %  N   %
Anxiety disorders
Generalized anxiety disorder 12 35.3   -   -
Panic disorder   8 23.5   2 11.8
Phobic disorders   6 17.6   -   -
Obsessive-compulsive disorder   3   8.8   -   -
PTSDa   -   -   4 23.5
Affective disorders
Major depressive disorder 20 58.8   -   -
Dysthymic disorder   7 20.6   -   -
Other disorders
Somatoform disorders 10 29.4   2 11.8
Dissociative disorders   6 17.6   1   5.9
Alcohol or drug dependence   4 11.8   3 17.7
Sleepwalking disorder   1   2.9   -   -
Any comborbid disorderb
No diagnosis   6 17.6 11 64.7
One diagnosis   5 14.7   2 11.8
Two diagnoses   7 20.6   2 11.8
Three diagnoses   2   5.9   -   -
Four or more diagnoses 14 41.1   2 11.8
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 In order to test whether the PANSS symptom profile of patients in the PTSD-SP 
subgroup diagnosed as DSM-IV ‘schizophrenia’ was more similar to the patients in 
the schizophrenia group of the current study or more similar to the psychotic disorder 
NOS subgroup, we conducted a MANOVA followed by discriminant analysis on these 
three groups: (1) the schizophrenia group (N=17); (2) the PTSD-SP subgroup 
Predicting diagnostic group status
Binary logistic regression analysis was applied to investigate whether a practical set 
of clinical features could predict diagnostic group status of the patients. Besides age 
and gender a set of four potential predictors was selected based on clinical 
usefulness: age of onset of the first psychotic episode, number of comorbid disorders, 
total score of negative symptoms, and number of experienced traumatic events.
These three variables predicted 90.2% of the patients correctly as belonging to the 
PTSD-SP or schizophrenia group (Nagelkerke’s adjusted R Square = 0.73, sensitivity 
= 91%, specificity = 88%, positive predictive value = 94%, negative predictive value 
= 83%). The number of comorbid disorders did not contribute significantly to this 
model nor did age or gender. 
PTSD-SP patients with and without a DSM-IV diagnosis of 
schizophrenia
In the schizophrenia  group all patients met DSM-IV criteria for schizophrenia, but in 
the PTSD-SP group the DSM IV diagnostic algorithms produced four different types 
of DSM-labels: ‘schizophrenia’ (35.3%), ‘schizoaffective disorder, depressive type’ 
(11.8%), ‘major depressive disorder, severe with psychotic features’ (8.8%), and 
‘psychosis NOS’ (44.1%). 
 First we were interested to know why part of the PTSD-SP sample did receive the 
diagnosis of schizophrenia, according to the current DSM classification system, while 
others did not. So we first compared PTSD-SP patients with DSM-IV schizophrenia 
(N=12) and PTSD-SP patients without DSM-IV schizophrenia (‘psychosis NOS’; 
N=15) on all PANSS ratings using t-tests. There was only one significant difference 
between these two PTSD-SP subgroups: in the DSM-IV schizophrenia subgroup the 
mean score of delusions was 4.33 (SD=1.16), while the mean score in the DSM-IV 
psychosis NOS subgroup was 2.33 (SD=1.63) (t=-3.72, df=24.9, p=0.001). 
Table 5   Variables contributed significantly to the model of predicting diagnostic 
group status of PTSD-SP versus schizophrenia
Variable B SE p odds 
ratio
95% CI
age of onset of the first psychotic episode - 0.14 0.06 0.020 0.86 0.77-0.97
total negative symptoms score   0.15 0.07 0.021 1.16 1.02-1.32
number of experienced traumatic events - 0.39 0.20 0.045 0.68 0.46-0.99
Figure 2   Canonical discriminant functions of three subgroups: 1. PTSD-SP 
subgroup classified by DSM IV as ‘psychotic disorder NOS’(n=15);  
2. PTSD-SP subgroup classified by DSM IV as ‘schizophrenia’ (n=12); 
3. Schizophrenia group classified by DSM IV as ‘schizophrenia’ (n=17).
Function 1: cognition; Function 2: emotional distress
60 61
Chapter 4 PTSD-SP and schizophrenia
4
symptoms in PTSD-SP patients started more than 10 years later than in schizophrenia, 
at least in males. These data, together with the MANOVA and discriminant analysis, 
suggest that PTSD-SP could be clinically different from schizophrenia and that 
PTSD-SP might be a valid new nosological entity. 
 Several other authors have published data that favour the classification of 
PTSD-SP as a separate diagnostic entity distinct from schizophrenia (2). For example, 
Sautter et al. (10) concluded that unlike schizophrenia, PTSD-SP was not associated 
with increased rates of familial psychosis. This suggests that PTSD-SP is a condition 
dissimilar to schizophrenia, since in the latter case family aggregation would be 
expected. This is supported by another study in which positive psychotic symptoms 
in patients with psychotic PTSD did not improve on risperidone treatment compared 
to placebo (23). Improvement would be expected if these symptoms were part of 
conventional psychotic disorders like schizophrenia or psychosis in bipolar disorder. 
The presence of unexpectedly low response rates in patients with PTSD-SP may 
indicate a different pathophysiology.. Other studies report additional differences in 
biological features between schizophrenia and PTSD-SP, such as disparities in 
corticotrophin releasing hormone (CRH) and dopamine beta-hydroxylase (DβH) 
levels, and differences in smooth pursuit eye movements (24).
 It is difficult to directly compare our findings with those of Hamner et al (11), because 
of the differences in sample (mixed gender sample of multi-ethnic refugees vs. male U.S. 
combat veterans) and differences in diagnostic procedures. Despite these important 
differences, we also found hallucinations to be similar in schizophrenia and PTSD-SP and 
conceptual disorganization to be much more severe in the schizophrenia group. However 
we did not find delusions to be more severe in the schizophrenia group nor did we find 
negative symptoms to be equally severe in both groups. 
 In our sample there were no other additional comorbid conditions that could 
account for the presence of psychotic symptoms in the ‘PTSD-SP group’. The most 
prevalent comorbid disorder in our sample that is known to have a psychotic subtype 
is major depressive disorder. Major depressive disorder with psychotic features 
might be responsible for the psychotic features in patients suffering from PTSD, 
suggesting that PTSD-SP, although different from schizophrenia, is not necessarily a 
valid separate nosological entity (12, 25). However, 41% of the PTSD-SP group in our 
study did not have a major depressive disorder, whereas in the remaining 59% only 
three patients (8.8%) were diagnosed as DSM-IV ‘major depressive disorder with 
psychotic features’. These, findings suggest that major depressive disorder is unlikely 
to account for the psychotic features in these patients; a finding similar to previous 
studies (1, 4) This conclusion is further supported by a study demonstrating that 
blood plasma levels of dopamine-beta-hydroxylase are increased in PTSD-SP 
patients while they are decreased in patients with major depressive disorder with 
psychotic features (26). 
classified by DSM IV as ‘schizophrenia’ (N=12); and (3) the PTSD-SP subgroup 
classified by DSM IV as ‘psychotic disorder NOS’ (N=15). We excluded PTSD-SP 
subjects with the other two DSM-IV diagnoses ‘schizoaffective disorder, depressive 
type’ (N=4), and ‘major depressive disorder, severe with psychotic features’ (N=3), 
due to the small numbers. Due to restricted power we did not use all PANSS items for 
this analysis but only those seven items that were significantly different (p<0.001) 
between the PTSD-SP and the schizophrenia group (see Figure 2). 
 Patients from both PTSD-SP subgroups (i.e. DSM-IV ‘psychotic disorder NOS’ 
and DSM-IV ‘schizophrenia’) were both significantly different from patients in the 
schizophrenia group based on their PANSS ratings. Using Pillai’s trace, there was a 
significant effect of group status on relevant PANSS symptoms (V=0.93, p<0.001). 
MANOVA was followed by discriminant analysis, which revealed two discriminant 
functions. The first function mainly consisted of cognitive symptoms (‘conceptual 
disorganization’, ‘lack of judgement and insight’, and ‘difficulty in abstract thinking’) 
and explained 96.5% of the variance (canonical R2=0.80; p<0.001). The second 
function mainly consisted of emotional distress and explained only 3.5% of the 
variance (canonical R2=0.13) and did not add significantly to the model (p=0.53). 
The correlations between diagnosis and discriminant function revealed that 
‘conceptual disorganization’ (r=0.77) and ‘lack of judgement and insight’ (r=0.53) 
contributed most to the discriminant function. This analysis revealed that patients of 
the PTSD-SP subgroup meeting DSM-IV criteria of schizophrenia were most similar 
to the PTSD-SP subgroup meeting DSM-IV criteria of psychotic disorder NOS, 
whereas both PTSD-SP subgroups together were significantly different from patients 
of the schizophrenia group of which all patients met DSM IV criteria of schizophrenia.
Discussion
PTSD with secondary psychotic features can be distinguished by clinical features 
from schizophrenia. A single prerequisite, whether PTSD preceded psychosis 
(PTSD-SP) or not (schizophrenia), defined two groups of chronic psychotic patients 
with considerable differences on many PANSS and some of the PSYRATS ratings. 
Patients of the PTSD-SP group had considerably less negative symptoms and less 
disorganisation than is commonly seen in schizophrenia and had more affective 
distress and more stress due to auditory hallucinations compared to patients in the 
schizophrenia group in this study. In addition, patients in the PTSD-SP group had 
many more comorbid disorders than patients in the schizophrenia group. PTSD-SP 
patients were also more depressed and anxious than patients suffering from 
schizophrenia and were more frequently traumatized. Another important feature that 
distinguished PTSD-SP from schizophrenia patients was that the first psychotic 
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symptoms, as well as more severe ones, compared to Euro-American patients (41). 
These African-American patients did not have increased rates of schizophrenia. 
Therefore, these differences may reflect ethnic and cultural differences in the 
symptomatic presentations of psychotic disorders and the authors warned against 
the risk of a misdiagnosis of schizophrenia. An alternative diagnosis of some of these 
patients might be PTSD-SP.  Indeed, several studies have mentioned that 
non-Caucasian ethnicity might be a risk factor for PTSD-SP (42-44). To our knowledge, 
only one study was designed to test the hypothesis that ethnicity may influence the 
clinical presentation and symptom pattern in PTSD-SP (42). They concluded that Af-
rican-Americans with PTSD endorsed more positive symptoms of psychosis, without 
higher rates of primary psychosis, depression, or anxiety than Caucasians. In our 
study PTSD-SP was seen in different groups of patients from a range of different 
cultures and with different trauma experiences. They were all refugees who left their 
country of origin and fled to the Netherlands. This fact increases the risk of developing 
PTSD (and possibly PTSD-SP) since, as reported by several studies on refugees 
mental health, protective factors are less likely to be present, such as the presence of 
an extended family, the opportunity to engage in meaningful cultural traditional 
practices or to recover from traumatic experiences  in the local community with family 
of friends with informal support systems (45, 46). Symptoms were reported to be 
more severe in patients, like in our study, who were displaced and spend a long time 
in asylum-camps (46-49). Taking this all into account we assume that PTSD-SP is not 
just a cultural specific syndrome. The potential influence of psychosocial and cultural 
factors in the development of PTSD-SP is certainly an issue for future research.
Conclusions
In conclusion, our study supports the validity of a new diagnostic entity called 
‘posttraumatic stress disorder with secondary psychotic features’. However, given 
the limited size and the specific nature of the sample and given the cross-sectional 
design, generalization of the main findings awaits replication in future research. 
Nevertheless our results are in line with result of several other studies mainly 
conducted among samples of war veterans.
Based on previous reviews (2, 24) and the current empirical study several criteria for 
PTSD-SP, as a provisional diagnostic entity, are beginning to take shape and should 
be exposed to future research: 
•­ diagnostic DSM-IV TR criteria of PTSD should be met, 
•­ positive psychotic symptoms such as delusions and/or hallucinations, 
•­ no formal thought disorder, 
•­ no conceptual disorganization, 
Our study has both strengths and limitations. The main strengths are the transparent 
way in which PTSD-SP and schizophrenia groups are separated, and the broad and 
in depth range of standardized symptom assessments. There are also limitations that 
should be considered. First, the sample sizes are fairly small. However, despite small 
sample sizes and notwithstanding adjustment of multiple comparisons, many 
significant differences between the groups were observed. Furthermore in order to 
support the correct interpretation by the readers, we added effect sizes if appropriate. 
Second, the differences in region of origin between the two groups may have 
influenced the results. However, there are no clear indications why and how that this 
should be the case. Third, there is growing evidence that (severe) childhood trauma 
contributes to the development of psychosis and schizophrenia in adult life (27, 28). 
Unfortunately, childhood trauma was not assessed in the current study and as a 
consequence we do not know whether (severe) childhood trauma is associated with 
(and thus a potential risk factor for the development of) PTSD-SP. Future research 
should clarify this issue. Another possible limitation of our study might be 
sampling-bias. The median age of onset of PTSD in our PTSD-SP patients was 29 
years. Cross-national population studies point to a wide distribution in the median 
age of onset of PTSD (between 25 and 53 years of age) and a broad inter-quartile 
range (IQR) of the age of onset (15 to 75 years) (29, 30). The median age of onset of 
our refugee sample clearly fits in this wide distribution. In a Dutch study the median 
age of onset of PTSD was 28 years in a representative random sample of non-institu-
tionalized inhabitants (31), while in the neighboring Belgium the median age of onset 
was 53 years in the adult general population (32). Sample selection may have had an 
influence on the median age of onset of PTSD also in our study among refugees. 
Finally, memory impairment or recall bias is known to exist in both patients with 
psychotic disorders and patients with PTSD. This poses some limitations regarding 
the accuracy of the retrospective assessments of the exact start of the chronic 
disorders in our sample and the amount and severity of life events. On the other 
hand, it is well known that trauma reports based on memories show at least fair to 
moderate test-retest reliability (33).
 Culturally determined idioms of distress may play an important role in the patho-
plasticity of psychotic symptoms (34-36). In a number of studies, African-American 
patients are reported to present with more symptoms and more severe psychotic 
symptoms than an otherwise similar group of Caucasian patients, independent of 
their diagnosis (37, 38). Similar findings were recently reported for Moroccan 
immigrant compared to native patients in the Netherlands (39, 40). The presence of 
these psychotic symptoms in patients with non-schizophrenic disorders may increase 
the risk of a misdiagnosis of schizophrenia (36, 37). In a study of 193 African- and 
Euro-American patients presenting for hospitalization with psychosis  Arnold et al 
concluded that African-American patients had a higher number of first rank psychotic 
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Introduction
Posttraumatic stress disorder (PTSD) is associated with an increased prevalence of 
psychotic symptoms both in the general population (odds ratio = 1,83) and in 
psychiatric out-patients (odds ratio 3.48) (1, 2). In part, this association has been 
explained by the fact that patients with schizophrenia are more likely to develop PTSD 
due to a higher risk of experiencing traumatic events related to their psychosis (3, 4). 
However, there is also a high co-occurrence of PTSD and psychosis in patients who 
do not suffer from schizophrenia. In this paper we focus on this latter condition, which 
has been labelled ‘posttraumatic stress disorder with secondary psychosis’ 
(PTSD-SP) (5-8). In this condition, patients who already developed PTSD, sooner or 
later started to suffer from delusions and hallucinations as well. These positive 
psychotic symptoms were not confined to episodes of re-experiencing or flashbacks, 
and, there was no history of schizophrenia prior to the onset of PTSD. In a previous 
paper, we have shown that PTSD-SP is not likely to belong to the schizophrenia 
spectrum (Braakman et al., submitted).
 Therefore, in this study, we investigate whether PTSD is more likely to be a subtype of 
PTSD or a separate diagnostic entity. First we explore the possibility that the psychotic 
symptoms in PTSD-SP can they be explained by other comorbid conditions common 
in PTSD, as Gaudiano and Zimmerman stated, such as major depressive disorder 
(affective psychosis) or substance-induced disorders (intoxication or withdrawal 
delirium) (1). Second, we investigate the possibility that the severity of the re-experiencing 
cluster in PTSD is associated with the presence of secondary psychotic symptoms in 
PTSD (9). Finally, we test whether more severe or specific traumatic events are 
associated  with the presence of secondary psychotic symptoms in PTSD (10).
 It is expected that improved diagnostic and etiological clarity might pave the 
road for future research into new treatment-approaches of this severe and chronic 
condition that does not respond adequately to the usual treatment options (6, 11).
Methods
Participants
We recruited two groups of refugee inpatients: refugees seeking treatment for PTSD 
patients without psychosis, and refugees seeking treatment for PTSD with secondary 
psychotic features. Patients were recruited in two mental health hospitals in The 
Netherlands that provide inpatient treatment for refugees. Participants were a 
consecutive sample of refugees who fled to the Netherlands from different parts of 
the world, were admitted to one of these two clinical facilities and met the following 
screening criteria: being a refugee, aged 16 years or older, at least one DSM IV PTSD 
Abstract 
Posttraumatic stress disorder (PTSD) is associated with the occurrence of secondary 
psychotic features, complicating treatment and resulting in negative outcomes. 
Some authors have suggested that PTSD with secondary psychotic features 
(PTSD-SP) is a diagnostic subtype of PTSD or even a separate diagnostic entity. 
However, other studies suggest that these psychotic features are just a form of 
psychiatric comorbidity, or a more severe form of re-experiencing symptoms, 
possibly related to a more severe or to specific kinds of traumatic events. In this study 
we, therefore, explore the nature of the association between PTSD and secondary 
psychotic features. In a cross sectional study among refugees, inpatients with PTSD 
with secondary psychotic features (PTSD-SP) (N=34) were compared to patients 
with PTSD without psychotic features (N=24) in terms of the prevalence of mental 
disorders associated with psychotic features, the intensity and frequency of 
PTSD-symptoms, and, the severity and kind of experienced traumatic events.
 The presence of secondary psychotic features in patients suffering from PTSD 
cannot be accounted for by psychiatric comorbid conditions, severity of re-experiencing 
or the severity of traumatic events. Together, these findings are less compatible with 
PTSD-SP as a subtype of PTSD than with PTSD-SP as a separate diagnostic entity.
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Data analysis
Sample size was calculated with G-power 3.1.3 (18). We were mainly interested in 
clinically relevant differences between the two groups. Therefore power calculations 
were based on large effect sizes (Cohen’s d = 0.8). Given a two-sided alpha of 0.05 
and a power of 0.80 we needed to include at least 52 patients to be divided into two 
groups. Variables were tested for normal distribution and homogeneity of variance. 
All tests were two-sided and p-values < 0.05 were considered significant. Effect 
sizes were computed if appropriate. Group differences were tested using t-tests for 
continuous variables and Fisher’s exact tests for categorical variables. If parametric 
assumptions were not met, independent samples Mann-Whitney tests were 
performed. All statistical data analyses were performed using PASW Statistics 18.0 
for Windows (SPSS/IBM Inc, Chicago, IL).
Results
Sample characteristics
A total of 150 consecutive inpatients were screened for eligibility. Using the inclusion 
and exclusion criteria mentioned before, the final study population consisted of 58 
subjects, 16 females and 42 males (Figure 1). Of these, 24 suffered from PTSD 
without psychotic features and 34 from PTSD with secondary psychotic features 
(PTSD-SP). Basic demographic variables were comparable for both groups (Table 1) 
except for region of origin. Patients originating from southern and eastern Europe 
were overrepresented in the PTSD-SP group, whereas patients from Africa and from 
southern and southeastern Asia were underrepresented in the PTSD-SP group. 
Patients in the total sample of 58 subjects belonged to 31 different ethnic groups. 
 In both groups the mean age of onset of PTSD was around 30 years of age. 
Patients suffering from PTSD-SP left their country of origin about 2.4 years after the 
onset of PTSD (95%CI = 1.3 to 3.5 years) while the PTSD group fled around the time 
of onset of PTSD (95%CI = -1.6 to 1.3 years; t=2.97, df=54, p=0.004). (Two extreme 
outliers from the PTSD-SP group were excluded (deviated >5 SD from the mean, 
remaining data were normally distributed).
Ten of the 34 patients with PTSD-SP (29,4%) developed their first psychosis before 
seeking refuge in the Netherlands, whereas nine patients (26,5%) became psychotic 
around their date of arrival in the Netherlands and 15 patients (44.1%) during the first 
years after arriving in the Netherlands. The mean length of residence in the 
Netherlands at the time of assessment was 7.3 years in the PTSD group (95%CI = 5.5 
to 9.1 years) which was significantly longer  than the length in the PTSD-SP group: 4,8 
years (95%CI = 4.0 to 5.7 years; t=2.79, df=56, p=0,015).
symptom or at least one psychotic symptom. All subjects meeting screening criteria 
were asked informed consent to participate in this study. Informed consent was 
obtained from all participants, and all study procedures were approved by the Dutch 
Mental Health Ethical Review Board (METIGG).
Diagnostic assessment and group allocation
All psychiatric diagnoses were based on extensive assessments with the Schedules 
for Clinical Assessment in Neuropsychiatry (SCAN) (12). The SCAN has been shown 
to be cross-culturally valid and applicable (13). All patients with a DSM-IV diagnosis 
PTSD were included. Patients with comorbid bipolar disorder, organic mental 
disorders or malingering were excluded. Similar to Sautter et al (8), we defined the 
group of patients with posttraumatic stress disorder and secondary psychotic 
features (‘PTSD-SP-group’) as those patients with DSM-IV PTSD and one or more 
psychotic symptoms, and with the onset of PTSD preceding the onset of the first 
psychotic symptom. Patients with psychotic symptoms prior to the onset of PTSD 
were excluded from this report. PTSD patients without current or life time psychotic 
features constituted the ‘PTSD group’. Patients of this PTSD-group met the PTSD 
criteria of the DSM IV and had no positive psychotic features outside re-experiencing 
episodes. We carefully distinguished psychotic symptoms from flashback episodes 
in which reliving the experience, illusions, and dissociative flashback episodes can 
occur. These latter symptoms were interpreted as part of the PTSD diagnosis. The 
Clinical History Schedule (CHS) of the SCAN provided dates on the onset of 
symptoms and disorders.
Symptom measures
The Clinician Administered PTSD Scale (CAPS) was used for a detailed assessment 
of the frequency and intensity of PTSD symptoms (14). The CAPS was performed by 
an experienced psychiatrist blinded for diagnostic group status. Severity of emotional 
distress (anxiety and depressive symptoms) was assessed with the Hopkins 
Symptoms Checklist (HSCL-25) (15). Finally, traumatic events were measured with 
the Harvard Trauma Questionnaire (HTQ). Cross-cultural psychometric properties of 
HTQ and HSCL-25 are adequate for the study population (16). The HTQ measures 
events that are most prevalent among refugees. The CAPS also contains a trauma-list 
in order to assess more general traumatic events, not specific for refugees (15, 17). 
All scales were completed in interviews by psychologists, blinded to diagnostic group 
status. In 80% of all interviews professional interpreters were required. 
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PTSD-SP and comorbidity
Comorbidity of both groups is summarized in Table 2. The vast majority in both groups 
had one or more current comorbid psychiatric disorders (83.3% in the PTSD group 
and 85.3% in the PTSD-SP group). 
Due to the higher percentage of patients in the PTSD-SP group with more than four 
comorbid disorders, patients in the PTSD-SP group had numerically more current 
comorbid disorders (mean 2.58; SD=1.97) than patients in the PTSD group 
(mean=1.83, SD=1.37), but this difference was not significant (t=1.72, df=55.9, p = 
Figure 1   Recruitment flow chart: subjects with ‘PTSD and secondary psychotic 
features’ and subjects with PTSD without psychosis
Admissions 150
Did not meet entry criteria 29
Eligible 
 (at least one PTSD symptom 
 or at least one psychotic symptom)
121
 Excluded due to short stay (< 2 months) 16
 Unable to test due to organic disorder or mutism 2
 Refused consent 17
Consented and SCAN assessment 86
  Excluded after SCAN assessment due to:  
bipolar disorder (n=4) missing data due  
to incomplete testing (> 2 missing  
symptom measures) (n=3) other diagnoses 
(subtreshold PTSD, n=2) malingering (n=2)
24
PTSD 62












the onset of 
first psychotic 
episode














Age in years 38.08 (11.82) 38.59 (9.99) 56 -  0.176 1) 0.860
Sex  males N (%) 16  (66.7%) 27 (79.4%) 1    1.192 2) 0.275 
Marital status    6.1443) 0.072
 Married 9 (37.5%) 20 (58.8%)
 Single 8 (33.3%) 12 (35.3%)
 Divorced 6 (25.0%) 2 (5.9%)
 Widowed 1 (4.2%) -
Years of education 10.0 (4.94) 8.5 (4.64) 52    1.156 1) 0.250
Religion    0.326 3) 0.878
 Islamic 10 (41,7%) 13  (38.2%)
 Christian 11 (45.8%) 15  (44.1%)
 Other 3 (12.5%) 6  (17.6%)
Region of origin    9.441 3) 0.022
 Southern & Eastern Europe 1 (4,2%) 12 (35,3%)
 Western Asia 6 (25,0%) 9 (26,5%)
 Southern & Southeastern Asia 7 (29,2%) 5 (14,7%)
 Africa 10 (41,7%) 8 (23,5%)
1) t-statistic;  2) Chi-square 3) Fisher’s exact test
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0.091). In both groups, the most frequent comorbid disorder group was major 
depressive disorder (41.7% vs. 67.6% in PTSD and PTSD-SP, respectively) followed 
by GAD (29.2% vs. 35.3%), but the differences between the groups were not 
significant.  The prevalence of alcohol or drug dependence was numerically higher in 
the PTSD group compared to the PTSD-SP group (25.0% vs. 11.8 %, respectively), 
but again this difference was not significant. 
 In the PTSD-SP group,  23 patients (67.6%) met criteria for a comorbid major 
depressive disorder and in only three of these patients the SCAN algorithm resulted 
in a diagnosis of major depressive episode with psychotic features. In 19 out of 23 
PTSD-SP patients suffering from a current comorbid major depressive disorder the 
temporal relationship between the start of the depressive episode and the start of the 
psychotic episode could be assessed. In 12 of these 19 patients the depressive 
episode started after the onset of the psychotic episode, whereas in three patients 
the depressive disorder started around the same time as the psychotic episode, and 
in four patients the depressive disorder started before the onset of the psychotic 
episode.
PTSD  symptomatology
Overall the CAPS revealed no significant differences in the prevalence or the intensity 
in PTSD symptoms. The only exception was ‘avoidance and numbing’ which was 
more intense in PTSD-SP group (p=0,002) with a large effect size (Cohen’s d = 0.92). 
PTSD and emotional distress
The mean HSCL-25 depressive symptom and mean anxiety symptom scores were 
not significantly different between the two diagnostic groups. However, the mean 
HSCL-25 emotional distress score was significantly higher in the PTSD-SP group 
(mean = 3.24, SD = 0.49) than in the PTSD group (mean = 2.98, SD = 0.41; t = 
2.074, df = 56, p = 0.043; d = 0.58). 
PTSD-SP and type and severity of traumatic events
The HTQ did not show significant differences in the type of experienced traumatic 
events between PTSD and PTSD-SP subjects (Table 3). In addition, no difference 
was found in the mean total number of experienced traumatic events: 10,3 (SD=4,1) 
in the PTSD-SP group versus 9,9 (SD=3,0) in the PTSD-group (t=0,31; df = 56 
p=0,755). The most frequent reported trauma in both groups was ‘being close to 
death’. 
The trauma rates determined with the CAPS showed no differences in experienced 
events: mean 9,7 events (SD=2.4) in PTSD group vs. mean 8,4 events (SD=2.6) in the 
PTSD-SP group (t=1,7; df = 56 p=0.085) (data not shown).














Generalized anxiety disorder 7 29.2 12 35.3 1.32 0.43-4.09
Panic disorder 3 12.5 8 23.5 2.15 0.51-9.15
Phobic disorders 2 8.3 6 17.6 2.36 0.43-12.84
Obsessive-compulsive disorder - - 3 8.8 - -
Any anxiety disorder
(in addition to PTSD)
7 29.2 18 52.9 2.73 0.90-8.28
Affective disorders
Major depressive disorder 10 41.7 23 67.6 2.93 0.99-8.65
Dysthymic disorder 5 20.8 7 20.6 0.99 0.27-3.58
Any affective disorder 14 58.4 26 76.5 2.32 0.75-7.22
Other disorders
Somatoform disorders 4 16.7 10 29.4 2.08 0.57-7.66
Dissociative disorders 3 12.5 6 17.6 1.50 0.34-6.70
Alcohol or drug dependence 6 25.0 4 11.8 0.4 0.10-1.61
Sleepwalking disorder 1 4.2 1 2.9 0.7 0.04-11.72
Any comorbid disorder
No diagnosis 4 16.7 5 14.7 0.86 0.21-3.61
One diagnosis 8 33.3 7 20.6 0.52 0.16-1.70
Two diagnoses 4 16.7 7 20.6 1.30 0.33-5.04
Three diagnoses 4 16.7 3 8.8 0.48 0.10-2.39
Four or more diagnoses 4 16.7 12 35.3 2.73 0.76-9.84
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Discussion 
Our main finding is that the emergence of psychotic symptoms after the onset of 
PTSD is not associated with and can thus not be explained by the presence of 
comorbid psychiatric disorders or the nature and severity of traumatic experiences..
Psychosis in PTSD-SP due to comorbidity?
Major depressive disorder
Major depressive disorder is the most common comorbid condition in the PTSD-SP 
group. However, the current data indicate that the presence of psychotic symptoms 
is not attributable to comorbid major depressive disorder. First, 11 of the 34 patients 
with PTSD-SP (32.4%) did not have a current diagnosis of major depressive disorder. 
Second, our data regarding the temporal relationships make it unattainable that 
comorbid major depressive disorder could account for the presence of psychotic 
features in the majority of patients, because the psychotic symptoms emerged before 
the onset of major depressive disorder in more than half of the patients with a mean 
time lag of more than three years. These findings are supported by several earlier 
clinical studies among US male war veterans (6) and one biological study in which 
plasma dopamine-beta-hydroxylase (DbH), the enzyme catalysing the synthesis of 
norepinephrine from dopamine, has shown to be increased in patients with PTSD 
and psychotic features compared to patients with PTSD without psychotic features 
(19), whereas plasma DbH is decreased in patients with major depression with 
psychotic features (20-22).
Substance-induced disorders
PTSD and substance use disorders frequently co-occur. Moreover substance use 
disorders are associated with the occurrence of psychotic features during intoxication 
or withdrawal. However, in the study only 4 of the 34 patients with PTSD-SP (11.8%) 
met criteria for and alcohol or drug use disorder and substance use disorders did not 
occur more frequently in PTSD-SP patients (11.8%) than in PTSD patients (25.0%). 
Therefore, it seems unlikely that this type of comorbidity is responsible for long lasting 
psychotic symptoms in patients with PTSD.
 In our study, none of the comorbid conditions known to be associated with 
psychosis were more frequent in the PTSD-SP group compared to the PTSD-group. 
These results are in contrast to a recent study by Gaudiano and Zimmerman (1). In 
their study among 378 PTSD patients, the rate of patients with PTSD and psychosis 
(n=38) dropped from 17% to only 2.5% (one patient) after excluding patients with 
comorbid conditions also known to be associated with psychotic symptoms. The 
authors suggested that it is the cumulative effect of a number of comorbid disorders 
that accounts for the strong association of PTSD with psychotic symptoms. It should 
Table 3   Comparing types of experienced traumatic events between the PTSD 
group and the PTSD-SP group assessed by the Harvard Trauma 
Questionaire (HTQ)
PTSD (N=24) PTSD-SP (N=34)
N % N %
Being close to death 17 70,8% 24 70,6%
Combat situation 16 66,7% 18 52,9%
Unnatural death of family or friend 16 66,7% 16 50,0%
Torture 16 66,7% 28 82,4%
Lack of food or water 15 62,5% 23 67,6%
Serious injury 15 62,5% 24 70,6%
Forced isolation from others 15 62,5% 25 78,1%
Lost or kidnapped 15 62,5% 20 66,7%
Lack of shelter 14 58,3% 16 47,1%
Murder of family or friend 14 58,3% 18 56,3%
Forced separation from family members 13 56,5% 27 84,4%
Murder of stranger or strangers 13 56,5% 16 48,5%
Imprisonment 13 54,2% 23 67,6%
Ill health without access to medical care 12 50,0% 23 67,6%
Rape or sexual abuse 9 37,5% 12 38,7%
Brainwashing 8 34,8% 9 29,0%
Any other situation that was very frightening 
or you felt your life was in danger
20 83,3% 28 87,5%
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presence of psychotic features in PTSD-SP patients as was previously suggested by 
Gaudio and Zimmerman (1). In addition, neither frequency/intensity of PTSD 
symptoms nor frequency/type of traumatic events were related to the presence of 
psychosis in patients with PTSD. Together, these findings are less compatible with 
PTSD-SP as a subtype of PTSD than with PTSD-SP as a separate diagnostic entity. 
Elucidating its aetiology and acknowledging PTSD-SP as a diagnostic entity will 
promote indispensable research into effective treatment options for this complex and 
often treatment resistant condition.
be noted, however, that Gaudiano and Zimmerman did not have data on the timing of 
the onset of psychotic symptoms and the temporal relationship with the psychotic 
symptoms and the comorbid disorders. In our study, temporal relationships revealed 
that comorbidity cannot explain the presence of psychosis in PTSD.
Psychosis in PTSD-SP linked to re-experiencing cluster of PTSD?
The CAPS data show that none of the posttraumatic stress symptoms are more 
frequent in PTSD-SP patients than in PTSD without psychotic symptoms. The same 
is true for the intensity of PTSD symptoms with the exception of the avoidance cluster 
(more intense in the PTSD-SP group). The fact that frequency and intensity of the re-
experiencing symptoms are similar in both groups suggests that the presence of 
psychotic symptoms cannot be explained by increased levels of re-experiencing, 
including intrusive memories and flashbacks. These findings are consistent with 
those of Sautter et al. in a population of US male war veterans (23).
Psychosis in PTSD-SP linked to trauma?
Both patients suffering from PTSD and those suffering from PTSD-SP experienced a 
high but very similar amount of traumatic events according to the HTQ and the CAPS. 
Neither the type of traumas nor their severity can explain the occurrence of psychotic 
symptoms in patients with PTSD-SP. These findings are consistent with the results of 
other studies among US war veterans. Wilcox et al. (24) found no association between 
the length of exposure in combat and the presence of auditory hallucinations. Hamner 
(25) reported that PTSD with psychotic features was not associated with impact of 
events, and Sautter et al. (23) have demonstrated that psychotic features of PTSD-SP 
were not related to combat exposure.
Study limitations
The major limitations of this study are its retrospective design and the limited sample 
size. Moreover, recall bias cannot be excluded, although there is no empirical 
evidence that recall difficulties differ between PTSD and PTSD-SP patients. 
 The main strength of the current study is that we were able to produce a more 
detailed description of the differences between PTSD patients with and without 
psychotic features than other studies. Prior studies had to rely on lifetime prevalence 
rates and were not able to take into account the temporal sequence of psychosis, 
PTSD and psychiatric comorbidity (1, 2, 7).
Conclusions
None of the comorbid conditions known to be associated with psychosis were more 
frequent in the PTSD-SP group compared to the PTSD-group without psychotic 
features. This makes it unlikely that comorbidity is a plausible explanation for the 
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Introduction
Posttraumatic stress disorder (PTSD) is frequently complicated by the co-occurrence 
of psychotic symptoms (1). There is increasing evidence that this condition called 
‘posttraumatic stress disorder with secondary psychotic features’ (PTSD-SP) has 
biological characteristics that are distinct from those of schizophrenia as well as 
those of PTSD without psychotic features (2, 3). About 15 years ago, Hamner and 
Gold published the results of an, as yet not replicated, study in which they reported 
an increased level of blood plasma activity of the enzyme dopamine β-hydroxylase 
(DβH) in patients with PTSD-SP compared to patients with PTSD without psychosis 
and to healthy controls (4). This finding is remarkable, since studies in several other 
psychiatric disorders with psychotic features have consistently found an association 
between lower plasma DβH and psychotic features (5). 
DβH is a critical enzyme that catalyzes the synthesis of noradrenalin from dopamine 
in sympathetic noradrenergic neurons. DβH enters the plasma after vesicular release 
from those neurons and the adrenal medulla (6). DβH plasma activity is very stable 
within subjects after the age of 5 years (5, 7) and thus is more ‘trait’ than ‘state’ 
related. Longitudinal repeated measures vary no more than 5-10% within subjects (7). 
However, inter-individual variation is high, due to the DBH -1021C>T (rs1611115) 
genetic single-nucleaotide polymorphism in the 5’ flanking region of the DBH gene 
(8, 9). Therefore, Cubells and Zabetian recommended in their review on DβH and 
psychiatric disorders to perform genotype-controlled studies (5). In three different 
ethnic groups (European Americans, African-Americans and ethnic Japanese), 
lowest mean levels of plasma DβH activity were found in homozygous TT subjects, 
CT heterozygotes showed intermediate mean levels, and CC homozygous subjects 
showed the highest mean levels. This polymorphism accounts for 35–52% of the in-
ter-individual variations in plasma DβH activity (5, 10, 11) within and across different 
ethnic groups. The association of the DBH -1021C>T polymorphism to plasma DβH 
activity was found to be far stronger than that of eleven other assessed SNPs evenly 
spaced across the DβH gene (5, 10). 
The purpose of the current study was to validate Hamner and Gold’s findings (4) in a 
larger, more varied group of subjects. We aimed to test whether DBH -1021C>T gen-
otype-controlled DβH plasma activity levels can be used as a biological marker for 
the development of psychosis in PTSD as some authors have suggested (4, 12). 
Hamner and Gold’s study had a very small sample size (6 patients with PTSD and 
psychosis and 13 patients with only PTSD), patients with PTSD and psychosis were 
not clearly defined, no patients with schizophrenia were included, and differences in 
DBH genotype or major depressive disorder were not taken into account as potential 
Abstract
Aim: The presence of secondary psychotic symptoms in patients with a posttraumatic 
stress disorder (PTSD-SP) complicates treatment compared to simple posttraumatic 
stress disorder (PTSD). A previous study among patients with PTSD and PTSD-SP 
suggested that the vulnerability towards developing psychotic symptoms in PTSD is 
associated with increased activity of dopamine beta-hydroxylase (DβH), a critical 
enzyme in the synthesis of noradrenalin from dopamine. The present study aimed to 
validate these findings in a larger, mixed gender, multi-ethnic sample, also including 
patients with schizophrenia, in order to evaluate whether plasma DβH activity is a 
biological marker for PTSD-SP. In addition, we also evaluated DBH -1021C>T 
(rs1611115) genotype because DβH plasma levels are under strong genetic control.
Methods: In a cross-sectional study, DβH plasma activity and DBH -1021C>T 
genotype were assessed in a consecutive series of patients with PTSD (n=17), 
PTSD-SP (n=27), schizophrenia (n=13) and in healthy controls (n=20).
Results: DBH -1021C>T genotype was strongly associated with plasma DβH activity 
in the ethnically heterogeneous sample (51.3% variance explained). However mean 
plasma DβH activity in patients with PTSD-SP was not different from that of patients 
with schizophrenia or PTSD or from that of health individuals, even after taking DBH 
-1021C>T genotype into account. The presence or absence of major depressive 
disorder in patients with PTSD-SP was not related to plasma DβH activity either. 
Conclusions: Plasma DβH activity does not seem to be a suitable biological marker 
for discriminating patients with PTSD from patients with PTSD-SP or schizophrenia. 
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3. Schizophrenia: the schizophrenia group was defined as those patients meeting 
DSM-IV criteria of schizophrenia with no history of PTSD prior to the onset of the 
first psychotic episode. 
In all groups, subjects with bipolar disorder, organic mental disorders or malingering 
were excluded. Patients were recruited from two mental health hospitals in The 
Netherlands that provide inpatient treatment to refugees originating from many parts 
of the world. Consecutive sampling was applied with recruitment of recently admitted 
patients meeting the following screening criteria: being a refugee, 16 years or older 
and showing at least one DSM-IV PTSD symptom or at least one psychotic symptom. 
After complete oral and written information about the study was given to the 
participants, written informed consent was obtained, together with the patient’s 
representative if applicable. Subsequently, the main diagnoses and comorbid 
disorders of patients were assessed with the Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN) (15). The SCAN has been shown to be cross-culturally valid 
and applicable (16). 
Besides these three patient groups, healthy controls were recruited from non-genet-
ically related family members, friends or acquaintances as well as subjects from 
regional refugee asylums. They were screened for the presence of psychiatric 
disorders with the Composite International Diagnostic Interview (CIDI), developed by 
the World Health Organization (17, 18). The CIDI is a cross-culturally validated 
diagnostic screening instrument and is well-fitted for use in the general population. 
Subjects meeting CIDI diagnostic criteria for any psychiatric diagnosis were excluded. 
Professional interpreters assisted in 80% of all interviews. All study procedures were 
approved by the Mental Health Institutions Ethical Review Board (METIGG). 
Dopamine β-hydroxylase activity and DBH genotyping 
All blood samples were collected between 9 and 11 a.m. to avoid potential diurnal 
variation of DβH plasma activity in individuals. Blood samples were prepared and 
stored at -70°C awaiting batch-wise analysis. All laboratory staff was blinded for 
group status. DβH activity was measured as follows (19): serum samples (50 μl) were 
mixed on ice with 100 μl water, 70 μl catalase (70 mg/ml in water; Sigma, St.Louis,USA) 
and 780 μl substrate buffer (250 mM Na-acetate [pH 5.0], 37.5 mM N-ethylmaleimide, 
31.25 μM CuSO4, 0.5 μM paragyline (Sigma), 125 mM Vitamin C, 125 mM Na-fumarate 
and 50 mM dopamine HCl). As a negative control 100 μl of 1mM fusaric acid (an 
inhibitor of DβH, Sigma) was used instead of water. Samples were then incubated at 
37°C for 25 minutes and put on ice again. Reaction was stopped by the addition of 
120 μl perchloric acid (60%) and 30 μl of 3,4-dihydroxybenzylamine hydrobromide 
confounders. Therefore, in the present study we included more patients with PTSD 
and psychosis, we clearly defined PTSD-SP as a condition in which PTSD preceded 
the onset of psychotic features, and we included a group of patients with a diagnosis 
of schizophrenia that was not preceded by PTSD. To be a useful biological marker for 
PTSD-SP, plasma DβH activity should at least be different between patients with 
PTSD-SP and healthy controls and/or patients with adjoining conditions like PTSD 
without psychotic features or schizophrenia. Since the majority of patients with 
PTSD-SP suffer from comorbid major depressive disorder and several studies have 
reported correlations between DβH plasma levels and major depressive disorder 
with psychotic features (7, 9, 13), we also evaluated possible confounding by major 
depressive disorder. Where Hamner and Gold’s study was conducted among male 
US war veterans with combat-related PTSD we included male and female refugees 
suffering from different kinds of traumatic events in our study. Taking into consideration 
the DBH -1021C>T genotype enabled us to adjust for the differences in the ethnic of 
the diagnostic groups.
In addition to attempting to validate Hamner and Gold’s findings, we also tested the 
hypothesis that plasma DβH activity was decreased in the schizophrenia group 
compared to normal controls and PTSD-SP patients. Finally, we hypothesized that 
there would be no direct relation between plasma DβH activity and major depressive 
disorder. If patients with PTSD-SP and major depressive disorder would be found to 
have lower levels of plasma DβH activity this would strongly suggest that these 
patients suffered from major depressive disorder with psychotic features, a condition 
shown to be associated with low DβH activity. In that case, PTSD-SP would less likely 
be a separate diagnostic entity.
Materials and Methods
Subject recruitment
This cross-sectional study recruited three groups of patients:
1. PTSD-SP: we defined this group of patients with posttraumatic stress disorder 
and secondary psychotic features similar to Sautter et al (14), as patients with 
DSM-IV PTSD and psychotic symptoms, in whom the onset of PTSD preceded 
the onset of psychosis. We carefully distinguished psychotic symptoms from 
(dissociative) flashback episodes with illusions and hallucinations while reliving 
the experience. These latter symptoms were interpreted as part of the 
conventional DSM-IV diagnostic criteria for PTSD.
2. PTSD: patients in the PTSD-group met the PTSD criteria of the DSM-IV and had 
no lifetime positive psychotic features outside re-experiencing episodes.
90 91




A total of 77 subjects participated in the study (Table 1), 17 with PTSD, 27 with 
PTSD-SP, 13 with schizophrenia and 20 healthy controls. Except for region of origin 
no significant differences were found between the groups. Religion was equally 
distributed between groups except for the healthy controls in whom Islamic subjects 
appeared to be overrepresented, although this effect was not statistically significant 
(p=0.67).
Genotype and plasma DβH activity
In the 77 subjects, the CC genotype was found in 62.3% (n=48), CT genotype in 
33.8% (n=26), and 3.9% (n=3) carried the TT genotype. As expected, there was a 
highly significant effect of genotype on plasma DβH activity (F (2,74)=27.1; p<0.001) 
with a mean plasma DβH activity of  28.3 U/l (95% CI = 23.1 - 33.6) in the CC group, 
15.6 U/l (95%CI = 11.5 – 19.7) in the CT group and, 1.1 U/l (95%CI = -0.2 – 2.4) in the 
TT group, respectively. Consistent with earlier findings, the distribution of plasma 
DβH activity was significantly non-normal (K-S test: D(78) = 0.120, p = 0.008) (9, 11) 
and therefore further analyses were performed on square-root transformed values. 
Since Levene’s test for homogeneity of variances was significant (p = 0.006) the 
one-way ANOVA was repeated  with the square-root plasma DβH activity as 
dependent variable. This also resulted in a significant effect of genotype on 
square-root DβH plasma levels (F = 13.2, df = 2, p<0.001, η2=0.26): 51.3% of the 
variance of square-root DβH plasma levels in this multiethnic sample was explained 
by the DBH -1021C>T genotype.
Diagnosis and DβH plasma levels
To assess the effect of DβH genotype on the relation between the square root of the 
DβH plasma activity and diagnostic group, we first assessed in a 2-way ANOVA 
whether the effect of diagnostic group on mean DβH plasma activity was modified by 
DBH genotype. This interaction effect was not significant (F(4,67) = 0.94; p = 0,445, 
partial η2  = 0.05) and subsequently the interaction term ‘diagnostic group * DBH’ 
was removed from the model. In this simplified model the square root of the the DβH 
plasma activity was not significantly related to diagnostic group (F(3,73) = 2.20; p = 
0.09, η2 = 0.08). Overall, plasma DβH activity was lower in the schizophrenia group 
compared to healthy controls (3.73 versus 5.10), but this difference was not statistically 
significant (see Table 2). 
In Figure 1 the mean square root plasma DβH activity of the four groups is represented 
by CC and CT genotype. TT genotype is not shown in this figure since only two of the 
four groups contain TT genotype and the numbers (n = 3) are too small.
(DHBA, Sigma, 1 mM). Samples were vortexed and centrifuged at 13,000*g for 5 
minutes. 700 μl of supernatant was loaded on a Sephadex G10 column, which was 
subsequently washed with 2 ml 0.03% formic acid and eluted with 2 ml 0.03% formic 
acid. To 1 ml of eluate 100 μl of reagent 3 of a catecholamine assay (catecholamine 
kit 195-5841/N, Acidic Reagent 195-6093 Reagent 3; Bio-rad, Hercules, California, 
USA) was added. The samples were analysed on an Allsphere ODS(2) column (25 
cm-4.6 mm-5 μm) (Altech, Breda, The Netherlands). Mobile phase consisted of 25 
mM citric acid, 25 mM Na2HPO4.2H2O , 0,7 mM sodium octanesulfonic acid (NaOcs), 
6.5 mM NaCl and 0,27 mM NaEDTA, 4% methanol, pH 3.5. The detection was 
performed by using an electrochemical detector (ESA, 425 mV; Interscience) at a 
flow of 1.50 ml/min. Enzyme activity was expressed in units per liter; 1 U/l was defined 
as the amount of enzyme needed to convert 1 M dopamine into 1 M noradrenalin per 
minute.
Genotyping of DβH was carried out at the Department of Human Genetics of the 
Radboud University Nijmegen Medical Centre. High molecular weight DNA was 
isolated from full blood, stored at -70°C before analysis. The DβH -1021C>T (rs1611115) 
polymorphism was genotyped using Taqman analysis (assay ID: C_11592758_10; 
Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). Genotyping was 
carried out in a volume of 10 μl containing 10 ng of genomic DNA, 5 μl of Taqman 2x 
Mastermix (Applied Biosytems), 0.375 μl of the Taqman assay and 3.625 μl of water. 
Genotyping was performed on a 7500 Fast Real-Time PCR System and genotypes 
were scored using the algorithm and software supplied by the manufacturer (Applied 
Biosystems). The genotyping assay had been validated before use. Testing for 
Hardy–Weinberg equilibrium did not show deviations from the expected genotype 
distribution (P>0.05). 
Statistical methods 
Variables were tested for normality with the Kolmogorov-Smirnov test. Homogeneity 
of variance was assessed with Levene’s test. We used (factorial) ANOVA and ANCOVA 
to assess group differences in DβH levels and chi square tests or Fisher’s exact tests 
for differences in categorical demographic variables. We used Sidak’s correction to 
correct for multiple comparisons. All tests were two-sided and p-values < 0.05 
corrected for multiple testing were considered significant. All statistical analyses were 
performed using PASW Statistics 18.0 for Windows (SPSS/IBM Inc, Chicago, IL). 
Sample size need was calculated with G*power (20). Based on Hamner and Gold’s 
reported large effect size (4) we set eta-squared at 0.14 and, with alpha set at 0.05 
and power at 0.80, a total sample size of 72 subjects appeared to be required.
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DβH and major depressive disorder
Finally we evaluated a possible correlation between plasma DβH activity and major 
depressive disorder in patients suffering from PTSD-SP. Within the PTSD-SP group 
we compared genotype-controlled DβH plasma activity between patients with and 
without major depressive disorder. Since TT genotype frequency was very low in the 
PTSD-SP group (n=2) this genotype was excluded from this subanalysis. Major 
depressive disorder was not associated with DBH genotype (X2(1) = 0.001, p = 
0.65). The mean plasma DβH activity in PTSD-SP patients with major depression 
(n=16) was higher (30.4 U/l; 95%CI= 22.2 - 38.7) than in PTSD-SP patients (n=9) 
without depression (20.5 U/l; 95%CI = 9.5-31.5), but this difference was not statistically 
significant (F(1,22) = 2.25, p = 0.15, partial ɳ2=0.09).
Discussion
This study did not find increased plasma DβH activity in PTSD-SP patients compared 
to PTSD patients or to healthy controls. Therefore, the current study did not validate 
the findings of Hamner and Gold (4). However, in line with earlier studies in subjects 
of European-American, African-American, Japanese, German and Croatian ancestry 
(11, 12, 21), this study confirmed, in a heterogeneous ethnic population, that plasma 
DβH activity is strongly associated with DBH -1012C>T genotype, with TT, CT, and, 
CC genotype showing low, intermediate and high plasma levels of DβH activity, 
respectively. 
 This inconsistency of our results and the increased levels of plasma DβH activity 
in PTSD-SP patients found by Hamner and Gold is unlikely to be explained by the 
lack of genetic control in the Hamner and Gold study, since also genetically 
uncorrected plasma DβH activity did not differ between the groups in our study. In 
addition, mean plasma DβH activity did not differ significantly between the 
schizophrenia group and the healthy controls. The latter is not surprising given the 
fact that plasma DβH activity was only found to be decreased in familial paranoid 
schizophrenia and not in other types of schizophrenia (5, 22). In our sample we did 
not differentiate between different schizophrenia subtypes, given sample size 
restrictions, and no information was available on the family history of schizophrenia 
patients. Finally, plasma DβH activity did also not differ between the schizophrenia 
group and the PTSD-SP and PTSD groups. Thus, based on these findings (geno-
type-controlled) plasma DβH activity is not a suitable biological marker to discriminate 
between PTSD, PTSD-SP and schizophrenia, nor is it suitable for differentiation of 
any of these disorders and healthy controls. 
 Interestingly, plasma DβH activity was not decreased in PTSD-SP subjects with 
major depressive disorder compared to PTSD-SP without major depressive disorder: 
Figure 1   Mean square root plasma DβH activity in four diagnostic groups by 
DBH -1021C>T genotype (CC,CT)
Error bars: 95% CI
n=10 n=14 n=8 n=16 n=7 n=11 n=4 n=4 
n=10 n=14 n=8 n=16 n=7 n=11 n=4 n=4 
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and not a variation of a major depressive disorder with psychotic features. Clinically 
this implies that patients with co-occurring PTSD, psychosis and major depressive 
disorder should not automatically be diagnosed or treated as patients with major 
depressive disorder with psychotic features. Instead, new treatment studies for 
patients suffering from PTSD with secondary psychosis (PTSD-SP) with or without 
concurrent depression are required.
there was even a non-significant trend for patients with PTSD-SP and major 
depressive disorder to have higher mean plasma DβH activity compared to PTSD-SP 
patients without major depressive disorder. Patients with major depressive disorder 
with psychotic features have consistently shown to have lower levels of plasma DβH 
activity compared to healthy controls (7, 9, 13, 23-25). Our findings therefore indicate 
that the presence of psychotic features in patients with PTSD-SP is unlikely to be 
explained by the presence of major depressive disorder with psychotic features since 
in that case plasma DβH activity would have been decreased. 
 The role of plasma DβH activity in PTSD-SP or in PTSD is still not fully understood. 
Mustaphic et al. found decreased levels of plasma DβH activity in war veterans 
homozygous for the DBH -1012C>T CC genotype compared to healthy subjects (12). 
We nor Hamner and Gold found these decreased levels (4). The role of DβH, 
dopamine as well as noradrenalin in PTSD and PTSD-SP is complex and remains 
unclear. Cubells and Zabetian (2004) suggested that lower plasma DβH activity are 
associated with higher vulnerability for psychosis, both in schizophrenia, major 
depressive disorder with psychotic features and paranoia after cocaine self-adminis-
tration (26). Indeed DβH inhibitors like fusaric acid and disulfiram predispose humans 
to psychosis (5). Low levels of DβH predicted disulfiram-induced psychosis in 
alcoholics (27), and inhibitors of DβH elevated dopamine/noradrenalin ratios (28) 
leading to psychosis. Cubells and Zabetian postulated a metabolic ‘bottleneck’: low 
DβH levels could lead to less efficient conversion of  dopamine to noradrenalin and 
hence to an elevated dopamine/noradrenalin ratio potentially leading to psychotic 
symptoms (5). This is in line with recent research in which hyperresponsiveness of the 
hypothalamic pituitary adrenal axis (as observed in PTSD) leads to (subcortical) 
dopaminergic dysregulation and psychotic symptoms (29-32). 
 Even though our study included more subjects than that by Hamner and Gold, 
the main weakness is still a limited sample size and thus a limited power to detect 
existing differences between groups. In addition we were not able to control for 
medication exposure. Most included patients used antidepressants and/or anti-
psychotics, and there is at least one study indicating that antipsychotics could 
decrease plasma DβH levels (33), although most authors agree that plasma DβH is 
a stable trait and not highly variable within individuals. Finally, biological studies, 
especially those including genetic data, can lead to non-significant results when 
conducted in ethnically and genetically non-homogenous samples like ours. 
The current study clearly shows that the presence or absence of major depressive 
disorder in patients with PTSD-SP is not related to plasma DβH activity suggesting 
that psychotic features in patients suffering from PTSD-SP and major depressive 
disorder are unlikely to be explained by the co-occuring major depressive disorder. 
This last finding strengthens the position that PTSD-SP is a distinct subtype of PTSD 
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“ Psychiatry is in the position—that most of medicine was in 200 years ago—of still 
having to define most of its disorders by their syndromes. Because of the consequent 
need to distinguish one disorder from another by differences between syndromes, 
the validity of diagnostic concepts remains an important issue in psychiatry” (1)
Introduction
This thesis examined the validity of ‘posttraumatic stress disorder with secondary 
psychotic features’ (PTSD-SP) as a separate diagnostic entity. First, we systematically 
evaluated the existing literature (in Chapter 2 and 3) using the validation strategy 
delineated by Robins and Guze (2) and refined by others (1, 3-5).  This strategy 
designated six criteria and all of them should be used simultaneously to assess the 
validity of a diagnostic concept:
1. Clinical description: identification and description of PTSD-SP
2. Delineation: clear boundaries of PTSD-SP with other, related, syndromes
3. Course: typical course and outcome of PTSD-SP
4. Treatment response: typical treatment effect in PTSD-SP
5. Family studies: PTSD-SP runs in families
6. Biological correlates related to PTSD-SP
With these criteria in mind, we assessed the validity of PTSD-SP as a separate 
diagnostic entity looking both at findings supporting and findings challenging the 
hypothesis that PTSD-SP is a separate diagnostic entity. In addition, we tried to 
identify domains in need for more scientific data to further elucidate the validity of the 
PTSD-SP-concept (Chapter 2 and Chapter 3).  Subsequently, we designed and 
conducted a study to resolve some of the remaining questions. This study focused 
on three of the six previously mentioned validity-criteria: clinical description, 
delineation from other syndromes, and biological correlates. In this final chapter we 
summarize our findings and conclusions and discuss the clinical implications and 
some suggestions for future research. 
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Results from our study (Chapter 4 and Chapter 5)
Symptoms: The symptom pattern of PTSD-SP in our population of refugees was 
very similar to  the symptom pattern in PTSD-SP patients described in our review of, 
mostly, war veterans. Severity of visual hallucinations and delusions in our PTSD-SP 
patients was similar to our patients with schizophrenia. However, auditory 
hallucinations were more severe in the PTSD-SP group compared to the schizophrenia 
group. This was mainly attributable to a more pronounced negative content of the 
voices and the higher intensity of experienced distress induced by hearing voices. 
Table 1 shows that our patients with PTSD-SP were much less disorganized,  showed 
considerably fewer negative symptoms and reported much higher levels of anxiety, 
depression and  tension than our patients with schizophrenia. Moreover, as a group, 
our patients with PTSD-SP had a better insight in their problems than our patients 
with schizophrenia.
 In our study, the Clinician Administered PTSD Scale (CAPS) revealed no 
significant differences between our patients with PTSD or PTSD-SP in the prevalence 
and the intensity in PTSD symptoms, with the  exception of ‘avoidance and numbing’ 
which was much more intense in the PTSD-SP group.  
 Finally, in our PTSD-SP group, the mean duration between the onset of PTSD 
and the onset of the psychotic symptoms was 4.5 years (SD=6.1); 20.6% developed 
a psychosis within 6 months after the onset of PTSD, 55.9% developed psychosis 
between 6 months and 5 years after the onset of PTSD, and in 23.5% of the patients 
the psychosis started more than 5 years after the onset of PTSD. 
 Age of onset: In our study we found a large and significant difference in the 
mean age of onset of the first psychotic episode between patients with PTSD-SP 
(34.4 years) and patients with schizophrenia (24.2 years) (Chapter 4).
 Traumatic events: In our study among refugees, like in clinical studies among 
war veterans, we found no differences in severity or the types of traumatic events 
between patients with PTSD-SP and patients with PTSD (Chapter 5). However, 
patients with PTSD-SP did experience more severe traumatic events than patients 
with schizophrenia. Ill health without access to medical care and rape or sexual 
abuse was reported much more often by the PTSD-SP group than by the schizophrenia 
group. 
Clinical description and the validity of PTSD-SP as a separate diagnostic 
entity
The fact that we found a symptom pattern in our patients with PTSD-SP that was 
distinct from our patients with schizophrenia and the fact that this symptom pattern in 
these patients with PTSD-SP in a multi-ethnic, mixed gender civilian population was 
very similar to the symptom pattern reported in studies among mainly male U.S. war 
veterans with PTSD-SP, strengthens the validity of PTSD-SP as a diagnostic concept. 
The evidence base of PTSD-SP as a separate syndrome
In this paragraph we discuss the available findings regarding the six criteria needed 
to accept PTSD-SP as a separate diagnostic entity. For each criterion, we start with a 
summary of the results from our reviews of the literature followed by the results of our 
own study and ending with an integration of these findings and a conclusion about 
each criterion.
Clinical description: identification and description of PTSD-SP
Results from our review (Chapter 2) and additional recent literature
Symptoms: A number of comparative studies have reported on patients first 
presenting a full-blown PTSD and subsequently reporting hallucinations and 
delusions. The nature of their hallucinations was mainly related to traumatic events 
and the content of their delusions was mainly paranoid and/or persecutory. These 
psychotic features were chronic and did not occur exclusively in the context of a re-
experiencing episode but were persistently present (see our review in Chapter 2). 
Patients with PTSD-SP seemed to suffer from a high burden of disease, similar to 
patients with schizophrenia and more than patients with PTSD without psychotic 
features (6). Since our review, several case-reports and case-series were published 
confirming this symptom pattern (7, 8). There was only one exception. In our review 
the presence of psychotic features was found not to be associated with the severity 
of PTSD as measured by the Clinician Administered PTSD Scale (CAPS) (Chapter 2), 
whereas in a recent study by Pivac et al. (9), patients with PTSD-SP reported much 
higher CAPS scores than PTSD patients (104.1 +/- 8.0 vs. 69.0 +/- 12.1).
 Traumatic events: Several studies have reported a dose-response relationship 
between the number of traumatic events, especially in childhood, and the risk of 
psychosis later in life (10-12). In a large community-based survey Scott et al. (13) 
found a significant dose-response relationship between the number and types of 
traumatic events and the endorsement of delusional experiences. In addition, Saha 
et al. (14) found in a large community sample that delusional-like experiences were 
not only increased in subjects with first exposure to trauma in childhood, but also in 
subjects with first exposure to trauma in adolescence or adulthood. However, in 
clinical populations of patients suffering from PTSD (mainly male US military veterans) 
with mainly adulthood trauma’s, the risk of subsequent manifestations of psychotic 
features was not related to the number, severity or the kind of traumatic events (see 
our review in Chapter 2). 
 Age of onset: In studies until 2008, age of onset of PTSD-SP has not been 
addressed systematically. Based on the studies included in our review (Chapter 2) we 
can only say that PTSD-SP seems to emerge in early adulthood or later in life (e.g. in 
war veterans). 
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trauma-related, but often these same patients also suffered from hallucinations with 
non-trauma-related content. Delusions in PTSD-SP patients were mainly paranoid 
and persecutory in nature, whereas in patients with schizophrenia the delusions were 
often more complex and bizarre. Formal thought disorders (e.g. loose associations, 
incoherence, neologisms) were quite common in schizophrenia but rare in PTSD-SP. 
No differences were detected between PTSD-SP and schizophrenia in the presence 
of negative symptoms. 
 Major depressive disorder: Comorbidity of major depressive disorder and 
PTSD varied between studies from 44 to 84%. Comorbidity between major depressive 
disorder and PTSD-SP was even higher. Moreover, there was a strong correlation 
between the severity of PTSD symptoms and the severity of depressive symptoms in 
PTSD-SP patients. Also PANSS-ratings of psychosis in PTSD-SP patients with major 
depressive disorder were higher compared to PTSD-SP patients without a 
co-occurring major depressive disorder. These findings suggested that PTSD, 
depressive disorder and psychotic features are somehow interconnected in patients 
suffering from PTSD-SP.  Based on these findings from the literature, it remained 
unclear to what extent psychotic features in PTSD-SP could be explained by the 
presence of a co-morbid psychotic depression. 
 Dissociative disorders: At the time of our review, there was only one study 
examining the co-occurrence of dissociative disorders and PTSD. In this study no 
relationship was observed between psychotic symptoms and dissociative features in 
patients with PTSD, as measured by the Dissociative Experience Scale (DES) 
(Chapter 2). However, a recent study by Anketell et al. (19) found a positive correlation 
between dissociative symptoms and PTSD in a group of chronic PTSD patients in 
Northern Ireland: PTSD patients with auditory hallucinatory experiences had higher 
scores on the dissociative experience scale compared to PTSD patients without 
auditory hallucinations. Unfortunately this study did not collect information on other 
comorbid conditions, e.g. schizophrenia was not excluded, and their assessments 
could not distinguish between benign hypnopompic/hypnagogic experiences and 
hallucinations or pseudo-hallucinations. Finally it remains unclear in this study 
whether auditory hallucinations were present prior to the onset of PTSD or appeared 
after the onset of PTSD.
 Substance-induced disorders: No relationships were found in studies before 
2008 between psychotic features in PTSD and alcohol or drug dependence, nor were 
psychotic features related to intoxication or withdrawal. A recent study (18) reported 
a significantly increased likelihood of a diagnosis of alcohol dependence in a group 
of PTSD patients characterized by high levels of psychotic features and high levels of 
PTSD symptoms. In this study, however, it remains unclear to what extend this group 
of PTSD patients is similar to the group of PTSD-SP patients, i.e. patients with PTSD 
and psychotic symptoms occurring after the onset of PTSD.
The same applies for the fact that neither the type nor the severity of traumatic 
experiences seems to be related to the risk of developing psychotic features after the 
onset of PTSD. Like Hamner (1997), we found no differences in PTSD symptom 
severity between patients with PTSD and patients with PTSD-SP (15); Chapter 4). 
However, in a recent study, Pivac et al. (9) found much higher CAPS scores in 
PTSD-SP patients than in PTSD patients; an inconsistency that needs further 
explanation. Finally, the discrepancy between the age of onset of first psychosis in 
the schizophrenia group and the PTSD-SP group is an important and significant 
distinction and favors the validity of PTSD-SP and helps us to delineate PTSD-SP 
from schizophrenia. In the next pages we take a more detailed look at the issues of 
delineation. 
Delineation: boundaries of PTSD-SP with other, related, syndromes
Results from our review (Chapter 2) and additional recent literature
Psychotic symptoms: Sareen et al. (16) examined the association of PTSD and 
positive psychotic symptoms in data from the U.S. National Comorbidity Survey Part 
II, a general population study with 5,877 participants. They found a strong association 
between PTSD and the presence of psychotic symptoms. Even after adjusting for a 
range of covariates, including psychiatric comorbidity, the relationship between 
PTSD and psychotic symptoms remained significant. This is in contrast with the 
findings of a more recent study among 1,800 U.S. psychiatric out-patients (17). In 
their report, the authors concluded that after excluding comorbid conditions, in which 
psychotic symptoms were prevalent, rates of psychotic  PTSD dropped dramatically 
and only one patient with “pure” PTSD-SP was left. In a re-analysis of the previously 
mentioned data from the U.S. National Comorbidity Survey Part II,  Shevlin et al. (18) 
excluded participants with a life time diagnosis of psychosis and applied latent class 
analysis to test whether a homogeneous group of PTSD patients could be identified 
with a psychotic subtype rather than simply a combination of PTSD and psychosis. 
Using this strategy, they found four groups of participants with PTSD, including two 
groups with a high probability of endorsing psychotic indicators. One of these two 
groups consisted of subjects with a high probability of PTSD symptoms in combination 
with a high probability of psychotic symptoms. The other group was characterized by 
a combination of a high probability of psychotic symptoms and a lower probability of 
PTSD symptoms. Unfortunately, none of the three studies made a clear and 
systematic distinction between subjects with PTSD preceding the onset of psychotic 
symptoms and patients with  psychotic symptoms who later developed PTSD .
 Schizophrenia: In the reviews in Chapter 2 and Chapter 3 we also looked for 
evidence showing that PTSD-SP could be differentiated from schizophrenia. 
Differences in symptom profiles were reported between patients with PTSD-SP and 
schizophrenia. The content of hallucinations in PTSD-SP patients was in most cases 
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Our study also provided strong clinical evidence that the psychotic features in 
PTSD-SP were not part of a (pre-existing) major depressive disorder or a dissociative 
disorder.
Biological correlates related to PTSD-SP
Results from our review (Chapter 2 and Chapter 3) and additional recent 
literature 
Our literature review suggested that platelet monoamine oxidase B (MAO-B) activity 
might be a useful biological marker of psychotic symptoms in PTSD-SP. Pivac et al. 
(20) found significant higher MAO-B activity in a group of war veterans with PTSD and 
psychotic symptoms compared to war veterans with only PTSD and war veterans 
without PTSD. However, until now very little is known about the pathophysiology 
behind this finding. In another report by Pivac et al. (21) war veterans with PTSD-SP 
had increased blood platelet-levels of serotonine (5-HT) activity compared to war 
veterans with PTSD,  war veterans without PTSD and healthy controls.
 Sautter studied differences in cerebrospinal fluid concentrations of corticotro-
phin-releasing hormone (CRH) and somatotropin-release-inhibiting hormone (SRIF) 
between 13 PTSD-SP patients, 8 patients with PTSD without psychosis and 8 healthy 
controls in an attempt to differentiate PTSD-SP as a subtype of PTSD from a schizo-
phrenia-related condition with comorbid PTSD (22). If PTSD-SP would be a 
complicated  subtype of PTSD they expected to find more extreme perturbations in 
the neuroendocrine patterns that characterize PTSD. They choose CRH and SRIF, 
because these hormones are known to be increased in PTSD (23, 24) and because 
CRH covaries with SRIF (25). They found significantly increased CRH in patients with 
PTSD-SP compared to patients with PTSD and healthy controls. SRIF was not 
significantly increased (22). Unfortunately, the study did not include patients with 
schizophrenia without PTSD.
 In another study, PTSD-SP was associated with smooth pursuit eye movement 
(SPEM) deficits that were qualitatively different from SPEM-deficits in patients 
suffering from schizophrenia as well as healthy controls: PTSD-SP patients were 
deficient in higher velocity SPEM compared to patients with schizophrenia (26). 
Significantly elevated plasma dopamine beta-hydroxylase (DβH) levels were 
observed in patients suffering from PTSD-SP compared to patients with non psychotic 
PTSD as well as compared to normal controls (Hamner and Gold, 1998). It is 
important to note that DβH is involved in the metabolization of dopamine into 
noradrenalin in noradrenalin nerve terminals.
 Finally, a recent study genotyped brain-derived neurotrophic factor (BDNF) 
Val166Met variants in 576 male Caucasian Croatian war veterans (9). War veterans 
with PTSD-SP (n=76) were more frequent carriers of one or two Met alleles than 
veterans with PTSD without secondary psychotic features (n=294) and combat- 
Results from our study (Chapter 4 and Chapter 5)
Schizophrenia: Although the presence of positive psychotic symptoms was similar 
in our patients with PTSD-SP and our patients with schizophrenia, conceptual disor-
ganization was less frequent in the PTSD-SP group. Importantly, our patients with 
PTSD-SP also reported markedly fewer negative symptoms, less lack of judgment 
and insight, much higher levels of anxiety and depression, and more comorbid 
psychiatric disorders compared to our patients with schizophrenia. Patients in the 
PTSD-SP group had about three times as many comorbid disorders as patients in 
the schizophrenia-group.  
 Major depressive disorder: In contrast to previous studies, we carefully 
analyzed the time of onset of PTSD, of psychosis and of major depressive disorder. 
About one-third of our PTSD-SP sample did not have a comorbid major depressive 
disorder and in 63%  of the patients with PTSD-SP and a comorbid major depressive 
disorder the onset of the first psychosis preceded the onset of the depressive 
disorder. Based on this analysis, we concluded that the emergence of psychotic 
symptoms in PTSD-SP can generally not be accounted for by the presence of a 
preceding comorbid major depressive disorder (Chapter 5). 
 Dissociative disorders: The finding of a lack of association between dissociative 
problems and PTSD was confirmed in our study (Chapter 5): comorbid dissociative 
disorders occurred in only 18% of our PTSD-SP patients, which was very similar to 
and not significantly different from the 13% in our PTSD group.
 Substance-induced disorders: We found not difference in prevalence of 
alcohol and drug use disorders between patients with PTSD-SP and PTSD (Chapter 
5), confirming previous findings from the literature (Chapter 2). However, the question 
remains unanswered why these findings are not congruent with the findings of Shevlin 
et al. (2010) showing an increased likelihood of alcohol dependence in their ‘high 
psychosis-high PTSD’-group (18).
Delineation and the validity of PTSD-SP as a separate diagnostic entity
Our study added new findings to support of the hypothesis that PTSD-SP can be 
delineated from other psychiatric disorders with psychotic features, such as 
schizophrenia, major depression with psychotic features, dissociative disorder, and 
substance-induced psychotic disorder. PTSD-SP and schizophrenia could be 
successfully differentiated by a limited set of clinical features: PTSD-SP patients had 
a much later age of onset of their first psychosis, PTSD-SP had remarkably fewer 
negative symptoms and PTSD-SP patients experienced many more traumatic events 
than patients with schizophrenia. In addition, as mentioned earlier, we found a much 
higher comorbidity in PTSD-SP compared to schizophrenia, a finding in line with the 
study by Shevlin et al., which identified a homogeneous high-psychosis and 
high-PTSD class which suffered from high comorbidity as well (18).  
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non-psychotic PTSD patients. A recent study provided support for this assumption 
since in that study PTSD-patients with psychotic symptoms were explicitly excluded 
and the remaining patients with non-psychotic PTSD did not show increased levels of 
CRH (32). Thus it might be that increased CRH is a feature of PTSD-SP and not of 
non-psychotic PTSD. 
 It should be noted, however, that (with the exception of plasma DβH levels, 
Chapter 6)  none of these biological studies have been replicated or validated in 
different settings or populations. and that our attempt the replicate the DβH findings 
of  Hamner en Gold (30) failed.
 However, our  DβH study did show that the psychotic symptoms of PTSD-SP are 
not very likely to be part of a comorbid major depression with psychotic features; a 
finding that corroborates the clinical evidence already reported in paragraph 2.2.2. 
Course, treatment response and family studies related to PTSD-SP 
As far as the criteria ‘course’, ‘treatment response’ and ‘family studies’ are concerned, 
we summarize them shortly in this paragraph and refer to Chapter 2 and 3 because 
no new data are available since our reviews and these criteria were not addressed in 
our own empirical study.
Results from our review (Chapter 2 and Chapter 3) and additional 
recent literature 
Course
No sound data are available in the literature on the clinical course of PTSD-SP except 
that PTSD-SP often is a chronic condition (33). 
Family studies
With regard to family studies, we reported in Chapter 2 the finding of one single study 
focusing on familial vulnerability to schizophrenia and other psychoses in first degree 
relatives of PTSD-SP patients (34). That study showed an increased prevalence of 
major depression, but no increased prevalence of psychotic disorders in first degree 
relatives. Neither our own study nor any new study published since that of Sautter et 
al. presented new family data.
Treatment response
As far as treatment response is concerned we reported the findings of four studies in 
which risperidone addition to SSRI’s and mono-therapy with quetiapine, olanzapine 
or fluphenazine were effective in the treatment of patients with PTSD-SP (Chapter 3). 
Compared to fluphenazine, olanzapine showed significantly (p<0.05) more 
improvement in negative symptoms and general psychopathology of the PANSS and 
in PTSD symptoms. Most studies were open-label, pre-post comparisons on the 
same subjects without comparison to placebo. Only one study included a placebo 
group and was double-blind (risperidone study by Hamner et al.  (35) In that study 
exposed veterans without PTSD (n=206). BDNF Met alleles are associated with 
psychotic symptoms in Alzheimer patients and in patients with schizophrenia and 
other psychotic disorders (9, 27, 28). The BDNF Met allele has also been found to be 
associated with impaired fear extinction (29).
Results for our study (Chapter 6)
We aimed to validate the DβH plasma findings of Hamner and Gold (30) in a study 
with larger samples and patients with schizophrenia as an additional comparison 
group. Since DβH plasma levels are under high genetic control we also controlled for 
potential differences in the DBH -1021C/T gene polymorphisms. We did not confirm 
the elevated DβH plasma levels in PTSD-SP patients compared to healthy controls, 
neither before nor after controlling for group differences in the DBH -1021C/T 
polymorphism. We also failed to find differences in  DβH plasma levels between 
patients with PTSD-SP and patients with schizophrenia or patients with PTSD without 
psychotic features. In the group of patients homozygous for the C-allele at DBH-1021 
we even found a decreased level of plasma DβH in PTSD compared to PTSD-SP, 
which was no longer significant after controlling for multiple comparisons. We also 
used major depressive disorder as a covariate in the relation between plasma DβH 
and PTSD-SP, because Cubells et al. (31) found in patients with major depressive 
disorder with psychotic features that the level of plasma DβH was lower than in 
healthy controls. However, plasma DβH levels in PTSD-SP were not lower than in 
PTSD in our sample and were not correlated with major depressive disorder and 
therefore we concluded that plasma DβH is not a suitable biomarker for PTSD-SP 
and that the psychotic symptoms in PTSD-SP are not very likely to represent the 
presence of a comorbid major depressive disorder with psychotic features.
Biological correlates and the validity of PTSD-SP as a separate diagnostic 
entity
Currently available studies provide some support for  PTSD-SP as a separate 
diagnostic entity. For example, the SPEM study clearly delineates PTSD-SP from 
schizophrenia, whereas the studies on CRH, MAO-B,  5HT and BDNF all found 
biological differences between PTSD-SP versus non-psychotic PTSD and healthy 
controls. The findings of Sautter et al. (22) support the hypothesis that PTSD-SP is a 
severe subtype of PTSD since the neuroendocrine perturbations were similar but 
more extreme compared to PTSD patients. Interestingly, in contrast to earlier studies 
that found increased levels of CRH in PTSD-patients (23, 24), Sautter et al. found no 
increased CRH in non-psychotic PTSD patients compared to healthy controls. A 
possible explanation for this might be that in those earlier studies PTSD-SP patients 
were not identified as such and therefore not excluded. Thus the increased CRH 
found in those studies might be due to PTSD-SP subjects and not due to the 
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diagnostic validators are investigated, however not replicated nor validated.  However, 
the response of PTSD-SP to present day treatment methods is unclear: several 
open-label studies point towards effective treatment with antipsychotic medication, 
however the only available randomized controlled trial showed only partial effects. 
Criterion 7 seems to be fully met: PTSD-SP contributes to better conceptualization of 
diagnoses, e.g. being able to discriminate the disorder from schizophrenia and major 
depressive disorder with psychotic features. Criterion 8 is also met: PTSD-SP can be 
differentiated from its nearest neighbours (schizophrenia, non-psychotic PTSD, major 
depressive disorder with psychotic features). Finally, criterion 9 is also met since 
acknowledging PTSD-SP as a separate diagnostic entity will lead to additional 
research, especially to search for the underlying mechanism and new treatment 
options. Moreover, it seems that the diagnosis PTSD-SP has no potential harms 
since it separates this condition from a even more stigmatized disorder like 
schizophrenia and it helps people to find the most appropriate treatment.
Strengths and weaknesses of the study
The main strength of our empirical study is that we were able to produce a more 
detailed description of the differences between PTSD patients with and without 
psychotic features than most other studies so far. An additional strength is that we 
studied a broader trauma cohort (male and female refugees) than in most other 
studies (only male war veterans). This increases the generalization of our findings 
regarding the PTSD-SP concept. Most importantly, other epidemiologic studies 
generally relied on lifetime prevalence rates and were not able to take into account 
the temporal sequence of psychosis, PTSD and psychiatric comorbidity (16-18). In 
contrast to that, we focused on the sequence of onset of PTSD, psychosis and 
depressive disorder. Therefore we were able to partially disentangle the complex in-
terrelationships between these disorders. 
 Our study also has limitations. The first limitation is its cross-sectional design 
with retrospective data collection. This is especially important in a study with psychotic 
and PTSD patients; a clinical population known to suffer from memory impairment, 
recall bias or under-reporting traumatic events (38, 39). This raises questions 
regarding the accuracy of the retrospective assessments of the exact start of the 
chronic disorders in our sample and the amount and severity of life events. On the 
other hand, it is well known that trauma reports based on memories show at least fair 
to moderate test-retest reliability (40) and there is no evidence that recall difficulties 
differ between schizophrenia, PTSD and PTSD-SP patients. A second important 
limitation is the fact that our sample size was not very large and that some of the 
observed (and often substantial) differences did not reach statistical significance due 
risperidone or placebo were added to an SSRI-regimen and a significant total 
improvement as measured with the PANSS was observed in the risperidone condition. 
However, closer examination revealed that neither the positive nor the negative 
psychotic symptoms improved but only the general psychopathology subscale of the 
PANSS. Our own empirical study did not contain any treatment data since this was 
not the objective of our study. 
The diagnostic validity of PTSD-SP
Clear distinctions are crucial for the recognition of clinical psychiatric syndromes as 
separate diagnostic entities  (1, 3-5, 36). We therefore used Robins  and Guze’s 
criteria to assess the validity of ‘posttraumatic stress disorder with secondary 
psychotic features’. Based on our reviews and our empirical study we conclude that 
substantial phenomenological and biological evidence is now available and that this 
evidence increases the likelihood that PTSD-SP can be delineated from other 
psychiatric disorders as a distinct psychiatric nosological entity. However to date 
there is no clear-cut and undisputed rule to affirm a nosological concept as sufficiently 
validated. As far as PTSD-SP is concerned, its validation is clearly strengthened yet 
several issues remain. 
Recently, Stein et al. (37) proposed the following criteria for a mental/psychiatric 
disorder to be included in DSM-5:
1. a behavioral or psychological syndrome or pattern that occurs in an individual
2. the consequences of which are clinically significant distress or disability
3. must not be merely an expectable response to common stressors and losses
4. that reflects an underlying psychobiological dysfunction
5. that is not primarily a result of social deviance or conflicts with society
6. that has diagnostic validity on the basis of various diagnostic validators (eg 
prognostic significance, psychobiological disruption, response to treatment)
7. that has clinical utility (e.g. contributes to better conceptualization of diagnoses, 
or to better assessment and treatment)
8. diagnostic validators and clinical utility should help to differentiate a disorder 
from diagnostic ‘nearest neighbors’
9. when considering whether to add a mental/psychiatric condition to the 
nomenclature potential benefits (better care, stimulate new research) should 
outweigh potential harms (e.g. be subject of misuse)
For PTSD-SP, many of these criteria are already met (1, 2, 3, 5, and 9). Criterion 4 is 
partially met: several studies point towards some specific psychobiological 
dysfunctions. However none of these has been replicated or validated and the exact 
psychobiological dysfunction of PTSD-SP is unknown. Criterion 6 is partially met: 
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b.  Psychoeducation is helpful in order to enhance feelings of control in patients as 
is focussing on the ‘here and now’;
c.  Therapists should, depending on the patient’s needs, be flexible and shift their 
treatment focus during the course of the disorder between emotional distancing 
(‘there and then’) of flashbacks i.a., and reintegration of dissociative symptoms 
(‘here and now’), and cognitive distinction of psychotic symptoms (to improve 
reality testing).
These are quite general recommendations indeed, relevant to all psychotic disorders. 
What is different is that in explaining the origin of psychotic experiences patients with 
PTSD-SP get a new framework in which their symptom and suffering are explained 
meaningfully. In addition, many patients feel embarrassed about psychotic symptoms, 
and do not easily disclose these symptoms (49), and, feel less stigmatized and seek 
more help when they notice that their psychotic symptoms are not labeled as 
schizophrenia but as part of their past traumatization (50). 
Pharmacotherapy
The best evidence for pharmacotherapeutic efficacy in PTSD-SP came from the 
randomized controlled trial by Hamner et al. (35). In this study risperidone or placebo 
were added to a standard regimen of antidepressant treatment. In this study, general 
psychopathology improved, but there were no differences in positive or negative 
psychotic symptoms between risperidone and placebo. Also re-experiencing 
symptoms improved. For the treatment of patients this could be helpful. However, it 
is interesting to note that psychotic symptoms did not respond like conventional 
psychotic disorders would.  All other studies are uncontrolled pre-post comparisons 
without placebo. Two of these reported significant improvements on risperidone and 
quetiapine mono-therapy in terms of a reduction of the majority of the psychotic and 
PTSD symptoms in these patients (51, 52). Another study compared olanzapine and 
fluphenazine as a mono-therapy in PTSD-SP patients in a six-week open label trial 
(53). Compared to fluphenazine, olanzapine showed significantly more improvements 
in terms of negative symptoms and general psychopathology on the PANSS and in 
PTSD symptoms. Based on my personal experience and two published case studies 
(54, 55), it seems that clozapine might be effective to remedy psychotic symptoms as 
well as PTSD and (other) anxiety symptoms in patients with PTSD-SP. 
 Given the present state of knowledge the best documented strategy is combining 
an SSRI with an atypical antipsychotic. Both agents are effective in treating PTSD 
symptomatology. In addition, although not yet conclusive, there is evidence that 
antipsychotics in PTSD-SP ameliorate general psychopathology. If this fails, based 
on clinical experience of several authors, clozapine could be the agent of last resort.
to a lack of statistical power. In order to recognize this limitation and to prevent type II 
errors in our conclusions, we also provided standardized effects sizes.  A third 
limitations is that we failed to assess childhood traumas in our study population, 
whereas there is growing evidence that childhood trauma contributes to the 
development of psychosis and schizophrenia in adult life (41, 42). Hence, it is possible 
that subjects who experienced childhood trauma are overrepresented in our PTSD-SP 
sample. However, there is no unambiguous evidence that subjects with childhood 
trauma are more prone to expose themselves to new traumatic events leading to 
PTSD in adult life and subsequently to psychosis. Future research should clarify this 
issue. A final limitation is the multi-ethnic nature of our study population; a condition 
that hinders the study of especially biological parameters, including genetics. 
Countless genetic studies found positive associations in ethnic homogeneous 
samples but failed to be replicated in other, ethnically different samples. In our study 
we used DBH-genotyping to control for ethic differences in our comparison of plasma 
DβH levels between the different diagnostic groups.
Clinical implications
Clinicians should be sensitized by this study in two ways. First of all, in the clinical 
assessment of psychosis it is important to check for the presence of trauma and 
PTSD. PTSD in psychotic patients is often missed  or underreported in charts (43-45). 
Closer examination could reveal that patients presenting psychotic features for a long 
time, and therefore being diagnosed as suffering from schizophrenia, might be 
incorrectly diagnosed and that PTSD-SP is a more appropriate diagnosis. Second, if 
PTSD-SP is different from schizophrenia, treatment options could be different as well. 
Accomplishing the most suitable diagnosis is not a goal in itself. It is in our opinion 
rather a means to achieve the best available treatment. Identifying PTSD-SP might 
prove to be important since common treatments used in schizophrenia have limited 
effect on positive and negative psychotic symptomatology, whereas interventions 
directed at the treatment of PTSD seem to have a beneficial effect (35, 46, 47).  Based 
on the few available studies to date the following tentative clinical recommendations 
can be made:
General recommendations
First, based on the description of three cases of refugees with PTSD-SP, Kurth et al. 
(48) mentioned several important treatment issues:
a.  Pharmacological treatment with antipsychotics is indicated and is helpful in 
stabilizing patients in such a way that additional psychotherapy is possible;
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study) and there are no studies focusing on the course of the disorder. Not all subjects 
develop PTSD after traumatization and not all individuals with PTSD develop 
secondary psychotic symptoms. It remains unclear ‘what makes the difference’. Nor 
is there convincing evidence whether PTSD-SP is fundamentally distinct from PTSD 
or whether it should be considered to be a subtype of PTSD. There is hardly any 
evidence focusing on the pathophysiology, the etiology or additional risk factors of 
the disorder. More neurobiological, gene-environment and psychological research is 
warranted to clarify these issues. 
 Most importantly treatment-intervention studies are still rare and further validation 
of PTSD-SP is necessary in order to pave the road for specific treatment intervention 
studies in the near future. 
Neurobiological research
A hypothetical model explaining the appearance of psychotic features in patients 
with PTSD-SP was developed by Hamner et al. (30). They propose that psychotic 
features in PTSD involve noradrenergic rather than dopaminergic hyperactivity. 
Studies suggest either elevated resting or exaggerated response of noradrenalin in 
PTSD (30, 59, 60). Furthermore, lots of studies have been conducted on noradrenergic 
hyperactivity and psychosis. Van Kammen et al. (1994) reported that increased 
central noradrenergic activity during chronic dopamine receptor blockade by 
haloperidol was associated with a high risk of relapse within six weeks after haloperidol 
withdrawal (61). Stressful events induce noradrenergic hyperactivity and even induce 
increased dopamine release. Finally, there is evidence that dysregulation of 
noradrenergic systems is induced by cortisol (62).
 Quite differently, Sautter et al (22) propose a dopaminergic theory. They have 
shown that unlike PTSD patients without psychosis, patients with PTSD-SP have an 
increased secretion of hypothalamic corticotrophin-releasing hormone (CRH). 
Increased CRH produces increased cortisol secretion. Increased cortisol levels leads 
to increased dopamine synthesis and increased dopamine release in the brain (63). 
Cortisol augments dopamine secretion especially in the mesolimbic system which is 
considered nowadays to be the cause of positive psychotic symptoms in patients 
with a psychotic disorder (62, 64, 65). At least two aspects of this theory need further 
empirical evidence. First, although still disputed, evidence suggests that in PTSD 
basal cortisol levels are not increased, even decreased (66). Thus empirical studies 
are needed to assess whether indeed cortisol levels in PTSD-SP are increased 
compared to non-psychotic PTSD. An as yet unpublished paper by Manguno-Mire et 
al. (67) demonstrates that subjects with PTSD and secondary psychotic features 
show significantly higher baseline cortisol levels than subjects with PTSD without 
psychotic features and control subjects. A second aspect of this theory that needs to 
be clarified is what explains the increased CRH in PTSD-SP.
Psychotherapy
Psychotherapy, especially focal exposure (47), cognitive behavioral therapy (CBT) 
and Eye Movement Desensitization Reprocessing (EMDR), appears to be the method 
of choice for the psychotherapeutic treatment of patients with PTSD-SP. The paper by 
Uddo et al (47) reported an improvement in PTSD-SP patients treated by focal 
exposure in group therapy. Unfortunately this study did not mention the instruments 
used to assess this improvement, nor the magnitude of the improvement. Therefore 
we could not include this study in our review (Chapter 2). However, recent studies 
suggest that CBT and EMDR could be effective in PTSD-SP based on the presumption 
that among the patients these studies included (schizophrenia with PTSD) some of 
them in fact could suffer from PTSD-SP since they did not screen for PTSD-SP nor 
did they map whether PTSD preceded or followed the onset of psychosis (56-58). 
The shortage of treatment studies is not only a consequence of insecure diagnostic 
status of PTSD-SP, but therapists as well as researchers are very reluctant to use 
exposure or CBT techniques in patients with psychotic symptoms. In a recent 
recruitment for a randomized clinical trial comparing psychotherapies for chronic 
PTSD, many enrollees (17%) reported psychotic symptoms and unfortunately were 
excluded from the study (50).  Both researchers and therapists have non-evidence 
based views that for instance exposure techniques would worsen psychotic 
symptoms or cause patients to decompensate. However, this might not be true (57, 
58). For example, a recent pilot study testing EMDR in a patient with a psychotic 
disorder and comorbid PTSD showed that this approach was safe (no deterioration 
of the psychotic symptoms) and effective in terms of a reduction of auditory 
hallucinations, delusions, anxiety, depressive symptoms and an improvement of 
self-esteem (56). 
Recognition of PTSD-SP as a valid diagnostic entity will facilitate clinical research into 
effective treatment options for this complex and difficult to treat psychiatric condition. 
Our study contributes to this validation process and, hopefully, stimulates more 
research into highly needed treatments for PTSD-SP.
Future research
We found important additional indications that PTSD-SP is either a distinctive 
nosological concept or a subtype of PTSD. We found clear evidence that PTSD-SP is 
different from (and the psychotic features cannot be explained by) schizophrenia, 
dissociative disorder, major depressive disorder with psychotic features and sub-
stance-induced disorders. However, more research is needed to further validate 
PTSD-SP.  For example, there is a paucity of family studies (just one unreplicated 
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Therapeutic research
Finally, of foremost concern, are studies focusing on effective treatment options, both 
in the area of medication and psychotherapy.
 As far as medication is concerned there are several options to be considered. 
First of all, several studies report improvements of PTSD-symptomatology by 
antipsychotic medication, especially second generation antipsychotics (77, 78) both 
as monotherapy as well as in addition to selective serotonine reuptake inhibitors 
(SSRI’s). However these studies present no clues as to which antipsychotics offer 
additional effects in PTSD-SP. None of the published pharmacological studies in 
PTSD-SP have been replicated and most are open label pre-post studies. Higher 
quality studies aimed at replication or validation are warranted. In addition trials 
comparing SSRI’s and antipsychotics could yield important data e.g. regarding the 
initial step in pharmacotherapy.
 If noradrenergic pathophysiology is assumed to be present, clonidine might be 
of interest. Clonidine is an alpha(2)-adrenoreceptor agonist and inhibits the 
spontaneous firing of brain norepinephrine (NE) containing neurons by its agonist 
action on the presynaptic alfa(2)-receptors. Alternatively, prazosine, an alpha(1)-adr-
enoreceptor antagonist which dampens noradrenergic function in different parts of 
the brain could be investigated (49).  
 Preliminary evidence suggests that CBT as well as EMDR might be of interest in 
PTSD-SP. Especially since CBT is effective in PTSD as well as in treating positive 
psychotic symptoms research into efficacy as well as side-effects is comprehensible. 
Psychotherapy trials explicitly designed to include patients suffering from PTSD-SP 
are warranted. This also applies for studies comparing psychotherapeutic 
interventions with pharmacotherapy.
Conclusion
In currently available studies we found support for PTSD-SP as a separate diagnostic 
entity. Our study added new findings to support this hypothesis. We produced a 
more detailed description of the differences between PTSD patients with and without 
psychotic features than most other studies so far, and we studied a different and 
broader trauma cohort (male and female refugees) than in most other studies (only 
male war veterans). We found evidence that PTSD-SP can be delineated from other 
psychiatric disorders with psychotic features such as schizophrenia, major depression 
with psychotic features, dissociative disorder, and substance-induced psychotic 
disorder.
 PTSD-SP and schizophrenia could be successfully differentiated by a limited set 
of clinical features. We found a symptom pattern in our patients with PTSD-SP that 
Psychosocial stress is associated with increased risk for developing psychosis, especially 
in case of cumulative exposure (68). If increased levels of basal cortisol appear before 
adolescence (e.g. due to childhood trauma) a cascade of events leads to a reduction of 
up to 33% of dopaminergic innervations of the prefrontal cortex in the brain of patients with 
schizophrenia (69). Maturation of the prefrontal cortex is not thought to be completed until 
early adulthood and might explain the severity of executive function deficits in schizophrenia 
(63). Since PTSD-SP develops much later in life compared to the onset of schizophrenia 
(Chapter 4, this thesis) and patients suffering from PTSD-SP mainly experience traumatic 
events in adulthood (of note: childhood traumatic experiences were not explicitely 
measured in our study), the prefrontal cortex is likely to be matured and thus increased 
cortisol levels give rise to mesolimbic dopamine hyperactivity, but prefrontal functioning is 
likely to be much more preserved compared to patients suffering from schizophrenia. This 
might explain the similarities (hallucinations and delusions) as well as the differences 
between patients with schizophrenia and patients with PTSD-SP (no conceptual disorga-
nization, no negative symptoms). This model presumes that basal cortisol levels are 
increased in PTSD-SP patients which to date is not yet clearly established. What we do 
know is that in PTSD without psychosis basal cortisol levels are not increased but rather 
decreased. What we do not know is if and how cortisol, as well as dopamine and 
noradrenalin are involved in the pathophysiology of PTSD-SP.  Future neurobiological 
studies could clarify these issues. To date neuroimaging studies are missing as far as 
PTSD-SP is concerned. Studies with several neuroimaging techniques (structural MRI, 
and PET or SPECT scans) could be useful in order to look for similarities and differences 
between patients with PTSD-SP and non-psychotic PTSD as well as schizophrenia. 
Structural neuroimaging studies with traumatized patients have reported findings similar to 
those in psychosis: thinning of the corpus callosum and reduced volumes in the anterior 
cingulated cortex and hippocampus (70-74). Of interest is what distinguishes PTSD-SP 
patients from patients with  these other disorders, e.g. hypo- or hyperfunctioning of parts 
of the prefrontal cortex.
Psychological research
There are several common psychological processes suggested in PTSD and 
psychosis and their relationship. Cognitive models in psychosis might explain how 
these processes are interrelated. Traumatized patients develop cognitions like “I am 
vulnerable” and “people can’t be trusted” (75, 76), which increases the risk of 
psychosis. Selective attention to threat is similar in paranoia and PTSD (76). Calvert 
et al. (75) suggest that cultural interpretations are important as well: if the interpretation 
of a post-traumatic intrusion is culturally acceptable both clinician and patient tend to 
favour PTSD as the diagnostic explanation. However if the link between symptoms 
and trauma is less obvious and culturally unacceptable, a diagnostic interpretation 
favouring psychosis is more likely (75, 76).
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was distinct from our patients with schizophrenia The discrepancy between the age 
of onset of first psychosis in our schizophrenia group and our PTSD-SP group is an 
important and significant distinction. It favors the validity of PTSD-SP and helps us to 
delineate PTSD-SP from schizophrenia. This also applies to the fact that the symptom 
pattern in these patients with PTSD-SP in a multi-ethnic, mixed gender civilian 
population was very similar to the symptom pattern reported in studies among mainly 
male U.S. war veterans with PTSD-SP.
 Our study also provided clinical evidence that the psychotic features in PTSD-SP 
were not part of a (pre-existing) major depressive disorder, both by analyzing the time 
of onset of PTSD, of psychosis and of major depressive disorder as well as by our 
findings that DBH plasma levels in PTSD-SP patients are not decreased, as is seen 
in patients with major depressive disorder with psychotic features. Also the psychotic 
features in PTSD-SP could not be accounted for by the presence of substance-in-
duced psychotic disorders or a dissociative disorder. Although we have obtained 
several facts indicating that PTSD-SP should be considered as a complicated 
subtype of PTSD or as a separate diagnostic entity more research is needed to 
address a number of unresolved issues. For example, little is known about the course 
of PTSD-SP or about its pathophysiology. Also, there is a paucity of family studies as 
well as neuroimaging data, nor do we have studies about the etiology and risk factors 
of PTSD-SP. The potential influence of psychosocial and cultural factors in the 
development of PTSD-SP, as well as the pathoplastic influence of cultural idioms of 
distress are issues for future research. And most importantly, much more research is 
needed concerning adequate and effective treatments.
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The study presented in this thesis originated from a clinical observation. During our 
clinical work in a psychiatric inpatient treatment facility for traumatized refugees and 
asylum seekers in the Netherlands we encountered many patients suffering from 
symptoms of posttraumatic stress disorder (PTSD) in conjunction with symptoms of 
chronic psychosis, especially delusions and hallucinations. These patients had 
developed PTSD and subsequently, sooner or later, psychotic symptoms as well. 
They had a remarkable poor response to antipsychotic medication. Questions  of 
referring psychiatrists about the diagnosis of these patients , as well as the repeatedly 
encountered treatment resistance of their chronic psychotic symptoms, paved the 
way for the main questions of this thesis. Before studies aimed at finding adequate 
and effective treatment options could be undertaken another important question 
emerged first: what is the diagnostic position of this manifestation of posttraumatic 
stress disorder and subsequent psychosis? Is it a form of (late onset) schizophrenia? 
Is it a complex PTSD? Is it a special kind of affective psychotic disorder? Or is it a 
diagnostic entity (PTSD-SP) on its own?  The goal of this thesis was to find evidence 
for the validity of this complex clinical picture as a separate diagnostic entity or to 
refute it. Is PTSD with secondary psychotic features a diagnostic entity on its own or 
could this syndrome appropriately be described by familiar and already existing 
diagnostic categories? 
First, in Chapter 2 and 3, we studied the present state of knowledge by an extensive 
survey of the literature.  Twenty-four  studies were identified with empirical data and 
minimum requirements regarding the level of evidence. From these studies PTSD-SP 
emerged as a syndrome that consists of posttraumatic stress disorder, joined by one 
or more psychotic features, especially hallucinations and delusions. The prevalence 
of PTSD-SP was unclear with varying rates of patients who looked for mental treatment 
(15-64%). The psychotic features were not confined to only the episodes of re-expe-
riencing, but persisted continuously. The content of these psychotic features was 
generally paranoid in nature, and no first rank Schneiderian psychotic features 
appeared to be present. There was no history of psychotic episodes prior to the 
traumatic event(s). There was no relationship between the nature or severity of the 
traumatic events and the presence of PTSD-SP. In first degree relatives of PTSD-SP 
patients there was an increased prevalence of major depression but no increased 
prevalence of psychotic disorders, which would be expected in cases of schizophrenia. 
Positive correlations of the secondary psychotic features in PTSD-SP patients were 
found with ethnicity (African-American and Hispanic), with co-morbid depressive 
disorder, with the enzyme-activity of DβH and with cerebrospinal fluid concentrations 
of CRF, blood platelet serotonine and MAO B activity. There were specific smooth 
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Major depressive disorder was the most common comorbid condition in the PTSD-SP 
group. 
Therefore, in Chapter 5, we explored the associations between psychotic features in 
PTSD-SP and other comorbid psychiatric conditions, especially major depressive 
disorder.  
Our data indicated that the presence of psychotic symptoms was not attributable to 
comorbid major depressive disorder since:
1.  in our study, 11 of the 34 patients with PTSD-SP (32.4%) did not have a current 
diagnosis of major depressive disorder. 
2.  in the remaining patients the psychotic symptoms emerged in the majority of the 
patients before the onset of major depressive disorder with a mean time lag of 
more than three years.
In Chapter 6 we aimed to validate a previous study by Hamner and Gold who reported 
an increased level of blood plasma activity of dopamine-β-hydroxylase (DβH) in 
patients with PTSD and psychotic symptoms compared to healthy controls and PTSD 
patients without psychotic features. We wanted to validate these findings in a larger, 
mixed gender, multi-ethnic sample and included also patients with schizophrenia. In 
addition, we evaluated DBH -1021C>T (rs1611115) genotype because DβH plasma 
levels are under strong genetic control. We found that DBH -1021C>T genotype was 
strongly associated with plasma DβH activity in the ethnically heterogeneous sample. 
Mean plasma DβH activity in patients with PTSD-SP was not different from that of 
patients with schizophrenia or PTSD or from that of health individuals, even after 
taking DBH -1021C>T genotype into account. The presence or absence of major 
depressive disorder in patients with PTSD-SP was not related to plasma DβH activity 
either. 
In the general discussion (Chapter 7) we reassessed our main research question 
whether PTSD-SP is a  diagnostic entity by combining the existing literature until 2008 
(at the start of our study), our own research findings and the findings from newer 
studies published from 2008 until 2012. We concluded that we have obtained 
numerous facts indicating that PTSD-SP should be considered as a (severe) subtype 
of PTSD or as a separate diagnostic entity. Nevertheless more studies are needed to 
address a number of unresolved issues. For example, little is known about the course 
of PTSD-SP or about its pathophysiology. And there is a paucity of family studies as 
well as neuroimaging data, nor do we have studies about the etiology and risk factors 
of PTSD-SP. This all might contribute to find more adequate and effective treatment 
options for this clinical syndrome.
pursuit eye movement deficits. Positive and negative psychotic symptoms did 
respond in uncontrolled pre-post comparisons with antipsychotics in some studies 
but not significantly compared to placebo in another study. Olanzapine treatment 
resulted in larger reductions in negative symptoms and PTSD symptoms than 
fluphenazine.
 In short, these two chapters summarized what was known about PTSD-SP and 
revealed the main gaps in the knowledge about this syndrome and the issues that 
needed additional empirical research.
Three principal research questions came forward out of this review of the literature:
1.  Can chronic psychosis in PTSD-SP be distinguished from psychosis in schizo phrenia 
by clinical features and trauma history?
2.  Can the presence of psychotic features in PTSD-SP be explained by psychiatric 
comorbidity, by more severe PTSD re-experiencing-symptoms, or by more 
severe or a specific type of traumatic events? 
3.  Is plasma dopamine beta-hydroxylase activity increased in posttraumatic stress 
disorder with secondary psychotic features?
To answer these questions we designed a cross sectional study in which we recruited 
adult refugee patients from two mental health hospitals in the Netherlands. As 
previous studies were almost exclusively limited to male outpatient war veterans from 
the U.S. exposed to combat-related trauma, we focused on a different and more 
diverse population: a multi-ethnic sample of refugees, both male and female, who 
had been exposed to a wide range of traumas, not exclusively combat-related. And 
next, as previous studies revealed that patients suffering from PTSD-SP had psychotic 
features similar but not necessarily identical to schizophrenia, we wanted to compare 
the psychotic features in both groups, PTSD-SP and schizophrenia, in order to 
determine similarities and/or differences between the two. 
This was the main objective of Chapter 4. We found that the clinical features of 
PTSD-SP can be distinguished from those of schizophrenia. Patients of the PTSD-SP 
group had considerably less negative symptoms and less disorganisation than is 
commonly seen in schizophrenia and furthermore they had more affective distress 
and more stress due to auditory hallucinations than patients in the schizophrenia 
group in this study. In addition, patients in the PTSD-SP group had more comorbid 
disorders than patients in the schizophrenia group. Patients with PTSD-SP suffered 
more from depressed and anxious feelings than patients who suffered from 
schizophrenia and they were more frequently traumatized. In males the first psychotic 




Het onderzoek dat in dit proefschrift wordt beschreven kwam voort uit de klinische 
praktijk. Werkend in een psychiatrische kliniek voor getraumatiseerde asielzoekers 
en vluchtelingen in Nederland troffen we veel patiënten aan die leden aan de 
symptomen van een posttraumatische stress-stoornis (PTSS) alsook aan chronisch 
psychotische symptomen, met name wanen en hallucinaties. Deze patiënten hadden 
eerst een PTSS ontwikkeld en daarna, vroeg of laat, kwamen daar psychotische 
symptomen bij. Deze psychotische symptomen reageerden erg slecht op antipsy-
chotische medicatie. Diagnostische vragen van verwijzers over dit beeld, alsook de 
frequente therapie-resistentie die we aantroffen bij deze patiënten gaven aanleiding 
tot de hoofdvragen van dit proefschrift. Alvorens in de toekomst onderzoek te kunnen 
doen naar adequate en effectieve behandelingen diende eerst een andere belangrijke 
vraag beantwoord te worden: hoe dient een posttraumatische stress-stoornis 
gevolgd door een psychose diagnostisch geïnterpreteerd te worden?  Is het een 
vorm van schizofrenie (met verlaat begin)? Is het een complexe PTSS? Is het een 
speciaal soort van affectieve psychotische stoornis? Of is het een diagnostische 
entiteit op zichzelf (PTSS-SP)? Het doel van dit proefschrift is om bewijs te vinden 
voor de validiteit van dit complexe klinische beeld als afzonderlijke diagnostische 
entiteit dan wel om dit te verwerpen. Oftewel in andere woorden: is PTSS met 
secundaire psychotische kenmerken (PTSS-SP) een diagnostische entiteit of kan dit 
syndroom beschreven worden door reeds bekende en bestaande diagnostische 
categorieën?
In hoofdstuk 2 en 3 bestudeerden we allereerst de bestaande kennis door een 
uitvoerig literatuur onderzoek. Vierentwintig empirische studies met een redelijk nivo 
van bewijs werden gevonden. Uit deze studies kwam PTSS-SP naar voren als een 
syndroom dat bestaat uit een posttraumatische stress-stoornis waaraan een of meer 
psychotische symptomen waren gekoppeld, met name wanen en hallucinaties. De 
prevalentie van PTSS-SP werd niet duidelijk, het prevalentie percentage onder PTSS 
patiënten die psychische hulp zochten voor hun klachten varieerde van 15 tot 64%. 
De psychotische kenmerken beperkten zich niet tot aanvallen van herbelevingen 
maar waren continu aanwezig. De inhoud van deze psychotische kenmerken was 
veelal paranoïde gekleurd en de symptomen van de eerste orde van Schneider leken 
afwezig te zijn. Er was geen voorgeschiedenis van psychotische episoden die vooraf 
gingen aan de traumatische gebeurtenissen. Er was geen relatie tussen de aard of 
ernst van de traumatische gebeurtenissen en het al dan niet verschijnen van een 
PTSS-SP. Bij eerstegraads verwanten van patiënten met een PTSS-SP werd wel een 
verhoogde prevalentie van depressie in engere zin gevonden maar geen verhoogde 
prevalentie van psychotische stoornissen, hetgeen wel verwacht zou worden indien 
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en minder desorganisatie dan men ziet bij de schizofrenie groep en verder hadden ze 
meer affectief onbehagen en meer stress door de auditieve hallucinaties dan patiënten 
uit de schizofrenie-groep. Bovendien hadden de patiënten van de PTSS-SP groep 
meer comorbide psychiatrische stoornissen en leden ze meer aan angst en depressieve 
gevoelens dan patiënten uit de schizofrenie groep en waren ze ook vaker getraumati-
seerd. Bij mannen begonnen de eerste psychotische symptomen meer dan tien jaar 
later dan bij mannen uit de schizofreniegroep. De depressieve stoornis was de meest 
voorkomende comorbide stoornis in de PTSS-SP groep.
 Vandaar dat we in hoofdstuk 5 zijn nagegaan of er associaties waren tussen 
de psychotische kenmerken bij PTSS-SP en andere comorbide psychiatrische 
stoornissen, met name de depressieve stoornis. Onze verkregen onderzoeks-
gegevens wijzen er op dat de aanwezigheid van psychotische symptomen niet 
toegeschreven kan worden aan een comorbide depressieve stoornis aangezien:
1.  in onze studie, 11 van de 34 patiënten met PTSS-SP (32,4%) geen comorbide 
depressieve stoornis hadden,
2. in de resterende groep patiënten in de meerderheid van de gevallen de 
psychotische symptomen ontstonden voordat de depressieve stoornis ontstond, 
gemiddeld zat daar drie jaar tussen.
In hoofdstuk 6 stelden we ons ten doel om de studie van Hamner en Gold te valideren. 
Deze auteurs hadden gerapporteerd dat de plasma dopamine-β-hydroxylase 
activiteit verhoogd was bij patiënten met PTSS en psychotische symptomen, 
vergeleken met gezonde controlepersonen en PTSS patiënten zonder psychotische 
kenmerken. We wilden deze bevindingen bevestigen in een grotere patientenpopula-
tie die multi-etnisch van aard was, zowel mannen alsook vrouwen bevatte en we 
wilden de plasma dopamine-β-hydroxylase activiteit ook vergelijken met een groep 
schizofrene patiënten. Bovendien hebben we tevens het DBH -1021C>T (rs1611115) 
genotype bepaald aangezien uit eerder onderzoek bleek dat de plasma dopamine-
β-hydroxylase activiteit in hoge mate door dit genotype wordt beïnvloed. We vonden 
inderdaad dat ook in deze etnisch heterogene populatie het DBH -1021C>T genotype 
in hoge mate correleerde met de plasma dopamine-β-hydroxylase activiteit. De 
gemiddelde plasma dopamine-β-hydroxylase activiteit van patiënten met PTSS-SP 
verschilde niet van die van patiënten met schizofrenie of patiënten met PTSS zonder 
psychotische kenmerken en verschilde evenmin van het gemiddelde van gezonde 
controlepersonen. Ook niet na correctie op de invloed van het DBH -1021C>T 
genotype. De aan- of afwezigheid van een depressieve stoornis bij patiënten met een 
PTSS-SP was niet gerelateerd aan de plasma dopamine-β-hydroxylase activiteit.
In de algemene discussie (hoofdstuk 7) hebben we opnieuw de vraag geëvalueerd 
of PTSS-SP een aparte diagnostische entiteit is, en wel deze keer door de bestaande 
deze patiënten aan schizofrenie zouden lijden. Bij PTSS-SP patiënten werden 
positieve correlaties gevonden tussen secundaire psychotische kenmerken met de 
volgende variabelen: ‘etniciteit’ (Afro-Amerikaans en Spaans-Amerikaans), ‘comorbide 
depressieve stoornissen’ , ‘verhoogde enzymactiviteit van plasma dopamine-β-
hydroxylase’  (DβH), ‘Corticotrophin Releasing Factor concentraties in de liquor 
 cerebrospinalis’  en ’serotonine’  en ‘ MAO-B activiteit in bloedplaatjes’ . Er waren 
specifieke oogbewegingsdefecten bij PTSS-SP patiënten. Positieve en negatieve 
psychotische symptomen reageerden weliswaar op antipsychotica in sommige 
studies met ongecontroleerde pre-post vergelijkingen echter niet in een studie die 
gebruik maakte van een placebo-groep.  Behandeling met olanzapine leidde tot een 
grotere reductie van negatieve symptomen alsook van PTSS symptomen dan 
flufenazine. Kortom, in deze twee hoofdstukken werd samengevat wat bekend was 
over PTSS-SP in de literatuur en dit leidde tot een overzicht van de belangrijkste 
lacunes en tot de themaɳs die nader empirisch onderzocht moesten worden.
Drie hoofdvragen kwamen uit dit literatuuronderzoek naar voren:
1.  Kan de chronische psychose in PTSS-SP onderscheiden worden van de 
psychose bij schizofrenie door klinische kenmerken en de traumatische voor-
geschiedenis?
2.  Kan de aanwezigheid van psychotische kenmerken bij PTSS-SP verklaard 
worden door de psychiatrische comorbiditeit, door mogelijk ernstigere 
symptomen uit het herbelevingen-cluster van de aanwezige PTSS of door 
ernstigere (of een specifiek soort van) traumatische gebeurtenissen?
3.  Is de plasma dopamine beta-hydroxylase activiteit toegenomen bij posttrauma-
tische stress stoornis met secundaire psychotische kenmerken?
Om deze vragen te beantwoorden werd een cross-sectionele studie ontworpen 
waarin we volwassen vluchtelingen/asielzoekers rekruteerden in twee psychiatrische 
ziekenhuizen in Nederland. Aangezien studies tot op heden voornamelijk werden 
verricht bij mannelijke, poliklinische oorlogsveteranen uit de VS die blootgesteld 
waren aan gevecht gerelateerde trauma’s wilden wij ons richten op een andere en 
meer gevarieerde populatie: een multi-etnische groep van vluchtelingen en 
asielzoekers, zowel mannen alsook vrouwen,  blootgesteld aan een breed scala van 
traumatische gebeurtenissen en niet louter gevecht gerelateerde trauma’s. Eerdere 
studies hebben laten zien dat patiënten die leden aan PTSS-SP psychotische 
kenmerken hadden die leken op schizofrenie. Daarom wilden wij de psychotische 
kenmerken van schizofrene patiënten en PTSS-SP patiënten met elkaar vergelijken 
om de overeenkomsten en/of verschillen tussen beide te kunnen vaststellen.
 Dit was de hoofddoelstelling van hoofdstuk 4. We vonden dat de klinische 
kenmerken van PTSS-SP onderscheiden kunnen worden van die van schizofrenie. 






Ik meende de kans op succes van mijn promotieonderzoek zo groot mogelijk te 
maken door het aantal mensen waarvan het onderzoek afhankelijk zou zijn zo klein 
mogelijk te houden. Onderstaand dankwoord toont aan hoe naïef dat was: onderzoek 
doen is een zeer sociale activiteit en de kans op succes van velen afhankelijk.
 Op de allereerste plaats gaat de grootste dank uiteraard uit naar de vele patiënten 
die bereid waren om aan het onderzoek mee te doen. De totale interviewtijd kon 
oplopen tot meer dan 20 uur per patiënt, zeker als we met tolken moesten werken. En 
dat bij psychisch veelal erg zieke mensen die de nodige ellende hebben meegemaakt 
in hun land van herkomst en daarna huis en haard hebben moeten ontvluchten naar 
Nederland alwaar ze vaak ten tijde van het onderzoek nog niet zeker wisten of ze wel 
mochten blijven. Deze dank geldt uiteraard ook voor alle gezonde controlepersonen en 
de talrijke controlepersonen waarvan we dachten dat ze gezond waren, maar na het 
interview toch moesten excluderen omdat we een onbehandelde psychiatrische 
stoornis ontdekten. Het bleek geen sinecure om psychisch gezonde asielzoekers/
vluchtelingen te vinden. In een adem noem ik dan ook de vele professionele tolken van 
het TVCN zonder wier hulp het onmogelijk was geweest de data te verzamelen, dank.
 Mijn dank aan mijn beide promotoren Prof. Dr. Frank Kortmann en Prof. Dr. Wim 
van den Brink is erg groot en dat niet alleen voor de wetenschappelijke input maar 
belangrijker nog  voor hun geduld en de enorme steun en oplossingsgerichte 
suggesties die ik kreeg tijdens de tegenslagen die ik in dit project te verwerken kreeg. 
Beste Frank, je stond mij terzijde vanaf het allereerste begin. Vanaf het jaar dat ik op 
zoek was naar een gepaste probleemstelling tot aan de dag van de promotie. Streng, 
veeleisend, uitdagend en nauwgezet. Dit kenmerkt je en heeft het eindresultaat erg 
verrijkt.  Onze overleggen waren vrijwel altijd zeer aangenaam en soms behoorlijk 
pittig en heftig, wetende dat onze band dat kon hebben. We vinden vast een 
aanleiding om ze in de toekomst voort te zetten.  Je leerde mij onder meer beter 
focussen en je verving mijn metaforische, wijdlopige schrijfstijl, me eigen gemaakt 
tijdens mijn studie antropologie , door een scherpere, kortere en eenduidigere me-
disch-wetenschappelijke manier van schrijven. We hebben binnen en buiten de 
transculturele psychiatrie veel samen opgetrokken en meegemaakt en ik verheug me 
er op dit te mogen voortzetten.
 Beste Wim, we maakten voor het eerst kennis tijdens de roemruchte Corsen-
donkcursus die toentertijd onder jouw leiding stond.  Met je innemende persoonlijk-
heid, je encyclopedische kennis over  de psychiatrische vakliteratuur en je duidelijk 
voelbare passie voor wetenschappelijk onderzoek liet je bij ons cursisten een 
blijvende en diepgaande indruk na. Kortom het was een voorrecht om door jou 
begeleid te mogen worden. Je liefde voor onderzoek werkt aanstekelijk en zal ik 
blijven koesteren.
literatuur die bekend was bij de start van ons onderzoek in 2008 te combineren met 
de bevindingen uit ons eigen onderzoek en ook de bevindingen van studies van 
anderen die sindsdien zijn gepubliceerd (tot en met 2012). We concludeerden dat we 
tal van feiten hebben opgespoord die er op wijzen dat PTSS-SP beschouwd zou 
moeten worden als een (ernstig) subtype van de posttraumatische stress-stoornis 
dan wel als een aparte diagnostische entiteit. Desalniettemin is er nog meer 
onderzoek nodig om een aantal nog niet opgeloste kwesties te beantwoorden. Zo is 
bijvoorbeeld weinig bekend over het beloop van PTSS-SP of over de pathofysiologie. 
Ook is er een schaarste aan studies onder verwanten van PTSS-SP patiënten en 
ontbreekt onderzoek op het gebied van neuro-imaging. Ook is er geen onderzoek 
naar de etiologie en de risicofactoren die leiden tot PTSS-SP. Al met al kan dit 




ers like you, suffer from traumatic experiences themselves. Hurricane Katrina hit your 
hospital in New Orleans. It vanished, together with your patients and research 
subjects, and your school had to downsize 180 faculty members in order to survive. 
Kartina damaged not only your career and private life, but our common research 
interest, psychotic PTSD, as well:  I sincerely hope that you manage to rebuilt your 
scientific infrastructure again and continue to publish on PTSD-SP.
 Dr. Joseph Cubells, dear Joe.  It was amazing to notice that you shared your 
basic data on DβH with me without any hesitation and without knowing me personally. 
It helped me to understand the distribution of DBH-plasma levels in relation to 
genotypes. Thanks for your advice. This is what scientific collaboration should be 
like.
 Velen meer ben ik dank verschuldigd, ik ga vast vele collega’s hier vergeten. Drie 
Nijmeegse hoogleraren wil ik in ieder geval niet vergeten en dat zijn Jan Buitelaar, 
Paul Hodiamont en Rutger-Jan van der Gaag. Jullie hebben me de ruimte gegeven 
om mee te doen met het promovendi-overleg, dan wel voor me een langdurige 
aanstelling bij het Radboud geregeld, dan wel me bij een dip een hoognodig 
ondersteunend zetje gegeven.
 De verpleegkundigen en andere medewerkers van Phoenix dank ik voor hun 
geduld en hulp voor als ik weer eens een patiënt nodig had voor het onderzoek en 
voor de vele discussies de we gevoerd hebben over het onderzoek en andere 
(transculturele) themaɳs. Vooral ook dank aan mijn directe ɳmaatjesɳ op Phoenix, te 
weten, Henriëtte (mijn steun door dik en dun, je hielp me met de begroting en de 
organisatie), Jolinda, Hanneke, Truus,  Willem en Douwe. Jullie hebben me steeds 
gesteund door de jaren heen. Dank Douwe voor de afname van de vele CAPS die je 
betrouwbaar en zeer nauwgezet voor me hebt afgenomen, en ja, ook jij hebt, net als 
ikzelf, de weg naar Noordwijkerhout diverse malen afgelegd. Eenzelfde woord van 
dank aan de sociotherapeuten, collega-psychiaters en andere medewerkers van de 
Vonk te Noordwijkerhout (Centrum ɳ45) voor het prettige samenwerken en jullie hulp. 
Ruim een jaar was ik elke dinsdag bij jullie en ik voelde me nog lang enigszins 
schuldig omdat ik vooral als onderzoeker kwam en niet zozeer de rol van psychiater-
behandelaar wilde oppakken toen Ronald wegging, terwijl jullie dat hard nodig 
hadden.
 Ronald Rijnders, destijds psychiater bij de Vonk in Noordwijkerhout, Ruud 
Jongedijk, directeur Zorg en Innovatie en  Jan Wilke Reerds, voorzitter van de Raad 
van Bestuur, allen van Stichting Centrum ɳ45, wil ik bedanken voor hun medewerking 
en gastvrijheid om ook patiënten van de Vonk in Noordwijkerhout te mogen includeren 
in het onderzoek. Dank ook Prof. Dr. Rolf Kleber, eveneens verbonden aan Centrum 
ɳ45. Rolf, in je hoedaningheid als voorzitter van de wetenschappelijke commissie gaf 
je mij toestemming om binnen de Vonk patiënten te includeren, mijn dank is groot, en 
ik hoop je in de toekomst weer vaker te zien.
Beste copromotoren, beste Robbert-Jan Verkes en Maarten Koeter, jullie raakten 
beiden vroeg bij het onderzoek betrokken. Over statistiek heb ik van jullie beiden veel 
geleerd en het is voor mij zelfs een passie geworden, en dat wil wat zeggen voor een 
met kwalitatief onderzoek opgeleide antropoloog. Ook dank ik jullie beiden voor de 
tips tijdens de uitvoering van de dataverzameling en de discussies over de 
interpretaties van de laboratorium uitslagen en andere resultaten en het opschrijven 
ervan. Ik zal blijven genieten van de prettige sfeer die jullie samen met Frank en Wim 
wisten te creëren.
 Dit onderzoek zou er niet geweest zijn zonder de financiële steun van het 
OOG-programma behorend bij GeestKracht van ZonMw, de Stichting tot Steun 
VCVGZ en Pro Persona. Ik ben hen dankbaar dat ze dit onderzoek financieel mogelijk 
gemaakt hebben, alsook voor het geduld en de adviezen die ik van hen kreeg.
De Raad van Bestuur van Pro Persona, met name in de persoon van voormalig 
voorzitter Christoph Hrachovec,  ben ik veel dank verschuldigd. Dank Christoph voor 
je vertrouwen dat ik dit project tot een goed einde zou brengen door me diverse 
malen te benoemen in functies die eigenlijk aan gepromoveerden waren 
voorbehouden. Dank ook voor het geduld dat jij (en Ron Akkerman) gehad hebben 
toen het allemaal ‘wat’ langer ging duren en vooral ook dank voor je ‘ongeduld’ aan 
het eind waardoor je me net dat ene zetje gaf dat ik nodig had om het manuscript af 
te ronden.
 Prof. Dr. Paul Hodiamont, Prof. Dr. Agnes van Minnen en Prof. Dr. Liewe de Haan 
ben ik, uiteraard, zeer erkentelijk voor het willen bestuderen van het manuscript en 
het groene licht dat ze me gaven.
 Dr. Ad Kaasenbrood en  Prof. Dr. Giel Hutschemaekers, beste Ad en Giel. Ook 
jullie stonden aan het begin van dit project. Ad, jou ben ik (nu) dankbaar voor het feit 
dat je me ooit dusdanig gemotiveerd hebt dat ik toch aan een promotie ben 
begonnen. En jij Giel, hebt me op weg geholpen om meer onderzoekstijd te kunnen 
krijgen naast mijn klinische werk en jij en Bea Tiemens hebben me fysiek en 
intellectueel onderdak verschaft om aan mijn onderzoeksvoorstel te schrijven. Ik mis 
die tijd nog steeds en we zien elkaar veel te weinig.
 Prof. Dr. Jim van Os, beste Jim, ik ben je dankbaar voor de uren die je in 
Maastricht voor me had uitgetrokken om mijn onderzoeksvoorstel met jou te 
bespreken alsook met de support die ik daarna nog af en toe van je kreeg. 
 Prof. Dr. Mark Hamner, dear Mark. Thank you very much for being one of the first 
and most prolific authors on PTSD and psychosis. You showed me the way and you 
supported my research proposal. 
 Prof. Dr. Frederic  J. Sautter , dear Fred. Although we’ve never met, I’m grateful 
for your publications that inspired me a lot and especially for sending me, without any 
hesitation, unpublished manuscripts of your work on cortisol and PTSD with 
secondary psychotic features. It was shocking to learn that eminent trauma-research-
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fase doormaken gedurende de looptijd van hun onderzoek. Bij mij heeft dat geleid tot 
een forse teruggang in de contacten met mijn vrienden. Gelukkig bleven jullie twee 
gewoon contact met me zoeken, ook al moesten jullie hiertoe veel vaker dan ik het 
initiatief nemen. Ik ben jullie hier zeer dankbaar voor en het is een eer en een 
genoegen dat juist jullie me als mijn paranimfen terzijde staan.
 Beste ouders, jullie hebben heel wat met me te stellen gehad. Dank voor alles, 
met name het laten merken  hoe trots jullie op mij en mijn prestaties zijn. Jammer pap, 
je hebt deze laatste etappe net niet meer mogen meemaken.
 Lieve Nina en Casper, ja ik ga meer tijd voor jullie krijgen. Het is heerlijk om jullie 
groot te zien worden, ik ben erg trots op jullie.
 Lieve Betty, je liet me vol geduld aan mijn proefschrift werken. Dat voelde 
fantastisch en je was daarin mijn steun en toeverlaat. En je greep gelukkig in als het 
echt te gortig werd. Je organiseerde tal van gelegenheden waarop we met zijn vieren 
van elkaar konden genieten, dat waren topmomenten. Ik hoop er nog zeer vele met 
je te mogen meemaken!
 Ik dank vooral ook jullie twee Nicole Pluim en Prisca Lichtendonk, ɳmijnɳ onder-
zoeksassistentes. Nicole, jij hebt de basis gelegd voor de interviews en de database 
die is opgebouwd. Ook jij ondernam regelmatig de lange reis naar Noordwijkerhout 
voor de interviews. Jij Prisca hebt de interviews afgerond, mij uit de brand geholpen 
toen we door de weggegooide buizen bloed ineens weer nieuwe patiënten moesten 
gaan includeren en je volharding heeft er ook voor gezorgd dat we het beoogde 
aantal gezonde controles uiteindelijk hebben gehaald.
 Lieve leden van de werkgroep trauma en neurobiologie van het eerste uur, 
Miranda, Carien, Ellen, Iva, Kathleen, Ethy, Mirjam, Thomas, Eric, Ronald, Elbert en 
vele anderen, jullie waren zonder het te merken een belangrijke motor die me 
draaiende hield. De vele praatjes die we onderling gaven, de vele interessante en 
veilige discussies en vooral ook de gezellige diners na afloop bleven me inspireren 
om door te gaan. 
 Tom Zewald, directeur in Wolfheze, je was de bestuurlijk verantwoordelijke voor 
het project en de stille kracht op de achtergrond die de financiën voor zover nodig 
voor je rekening nam. Ik dank je voor de aangename wijze waarop je dit voor me 
gedaan hebt.
 Medewerkers van het laboratorium in Wolfheze en Arnhem ben ik erkentelijk voor 
hun nauwgezette werk gedurende de jaren van het bloedprikken. Dank ook aan Kurt 
Quarz voor de zeer professionele wijze van het organiseren van onder meer de 
verwerking en opslag van de bloedbuizen. Marcel Verbeek  dank ik voor de snelle 
bepalingen van de enzymactiviteit en Prof. Dr. Barbara Franke voor het overleg en de 
bepaling van de genetische informatie de we nodig hadden. Barbara, ik zal niet 
vergeten hoe je een keer, ergens in het verre Azië een mail van me kreeg met een 
concept artikel dat je op zeer gedetailleerde en uiterst zorgvuldige wijze van 
commentaar hebt voorzien, dank.
 Martin van Veen en Henk Cloosterman, beste Martin en Henk, als ik weer eens 
publicaties niet te pakken kon krijgen in de digitale tijdschriftenbestanden van de 
universiteitsbibliotheek wisten jullie me in recordtempo toch aan de hoognodige 
publicaties te helpen, hulde.
 Mijn arts-assistenten in opleiding dank ik voor het geduld dat ze soms met me 
moesten hebben als ik weer eens vlak voor een deadline zat. Het is en blijft een 
voorrecht om jonge dokters te zien uitgroeien tot bekwame specialisten.  
 De leden van de Dominicaanse communiteit in Huissen dank ik zeer voor hun 
gastvrijheid, de gesprekken en het mogen deelnemen aan hun dagelijks kloosterritme. 
Het stelde me in staat om in korte tijd flinke sprongen te maken met de analyses en 
het schrijven van mijn proefschrift.
 Beste paranimfen, lieve Frans en Annemieke, ik ken jullie al heel lang, vanaf het 
begin van mijn studententijd. Ik vermoed dat onderzoekers die tegelijkertijd in de 
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middelbare school volgde hij in Kerkrade-West bij de scholengemeenschap Sancta 
Maria alwaar hij in 1979 het VWO-eindexamen Atheneum B behaalde. Hij studeerde 
Geneeskunde aan de Katholieke Universiteit te Nijmegen, de huidige Radboud 
Universiteit. Na het behalen van zijn kandidaats Geneeskunde begon hij daarnaast 
ook aan de studie Culturele Antropologie eveneens aan de Radboud Universiteit. 
Gedurende deze twee studies studeerde hij tevens aan de Leidse Universiteit een 
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Daarnaast is hij redacteur van de rubriek 'transculturele psychiatrie' van www.
psychiatrienet.nl en heeft hij nog een aantal landelijke functies. Hij woont met zijn 
vrouw, dochter en zoon in de Overbetuwe.

